5,6-Unsaturated Bicyclic Heterocycles Useful as Inhibitors of NOD-Like Receptor Protein 3

Abstract

The novel compounds of structural formula (I) and their pharmaceutically acceptable salts, hydrates, and solvates are inhibitors of NLRP3 and may be useful in the treatment, prevention, management, amelioration, control, and suppression of diseases mediated by NLRP3. The compounds of structural formula I may be useful in the treatment, prevention, or management of NLRP3-mediated diseases, disorders, and conditions (such as, but not limited to, gout, pseudogout, CAPS, NASH, fibrosis, heart failure, idiopathic pericarditis, atopic dermatitis, inflammatory bowel disease, Alzheimer's disease, Parkinson's disease, and traumatic brain injury). [Formula 1] TIFF0007815552000060.tif33130

Description

[Technical Field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. Provisional Patent Application No. 63 / 505,807, filed June 2, 2023, the entire contents of which are incorporated herein by reference. [Background technology]

[0002] Inflammasomes function as central signaling hubs in the innate immune system. They are multiprotein complexes that assemble after intracellular pattern recognition receptors (PRRs) are activated by various pathogen-associated molecular patterns (PAMPs) or danger-associated molecular patterns (DAMPs). Nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs) and pyrin- and HIN200-domain-containing proteins have been shown to form inflammasomes (Van Opdenbosch N and Lamkanfi M. Immunity, 2019 Jun 18;50(6):1352-1364). Inflammasome activation triggers a cascade of events that release inflammatory cytokines and promote a form of inflammatory cell death called pyroptosis, which is induced by the activation of gas dermins. Pyroptosis is a unique form of inflammatory cell death that not only results in the release of cytokines but also in the release of other intracellular components that promote a broad range of immune responses in both the innate and adaptive immune systems. Thus, inflammasome activation is a key regulator of the inflammatory cascade.

[0003] The NOD-like receptor protein 3 (NLRP3) inflammasome is the most well-studied of all inflammasomes. NLRP3 can be activated by numerous stimuli, including environmental crystals, pollutants, host-derived DAMPs, and protein aggregates (Tartey S and Kanneganti TD. Immunology, 2019 Apr;l56(4):329-338). Danger-associated molecular patterns that engage NLRP3 include uric acid and cholesterol crystals, which contribute to gout and atherosclerosis, amyloid P fibrils, which are neurotoxic in Alzheimer's disease, and asbestos particles, which contribute to mesothelioma (Kelley et al., Int J Mol Sci, 2019 Jul 6;20(13)). Furthermore, NLRP3 is activated by infectious pathogens such as Vibrio cholerae, fungal pathogens such as Aspergillus Jumigatus and Candida albicans, adenovirus, influenza A virus, and SARS-CoV-2 (Tartey and Kanneganti, 2019 (see above); Fung et al. Emerg Microbes Infect, 2020 Mar 14;9(1):558-570).

[0004] The mechanism of NLRP3 activation in humans remains unclear. It has been suggested that the NLRP3 inflammasome requires both transcriptional and post-transcriptional regulation (Yang et al., Cell Death Dis, 2019 Feb 12;10(2):128). The NOD-like receptor protein 3 (NLRP3) is a protein-coding gene encoding a protein consisting of an N-terminal pyrin domain, a nucleotide-binding domain (NBD), and a leucine-rich repeat (LRR) motif at the C-terminus (Inoue et al., Immunology, 2013, 139, 11-18; Sharif et al., Nature, 2019 Jun;570(7761):338-343).

[0005] In response to sterile inflammatory danger signals (PAMPs) or DAMPs, NLRP3 interacts with the adaptor protein, apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), and the protease caspase-1 to form the NLRP3 inflammasome. Upon activation, procaspase-1 undergoes autoproteolysis and cleaves gasdermin D (Gsdmd) to generate the N-terminal Gsdmd molecule, thereby forming pores in the plasma membrane and inducing lytic cell death termed pyroptosis. Alternatively, caspase-1 cleaves the proinflammatory cytokines pro-IL-Iβ and pro-IL-18, releasing their biologically active forms (Kelley et al., supra). Activation of the NLRP3 inflammasome leads to the release of the proinflammatory cytokines IL-Iβ (interleukin-Iβ) and IL-18 (interleukin-18), whose dysregulation can cause numerous diseases.

[0006] Dysregulation of the NLRP3 inflammasome or its downstream mediators is associated with many immune, inflammatory, autoimmune, and autoinflammatory diseases. NLRP3 inflammasome activation has been associated with the following diseases and disorders: cryopyrin-associated periodic syndrome; sickle cell disease; systemic lupus erythematosus; allodynia; graft-versus-host disease; liver disorders such as non-alcoholic steatohepatitis (NASH), chronic liver disease, viral hepatitis, alcoholic steatohepatitis, and alcoholic liver disease; inflammatory bowel diseases such as Crohn's disease and ulcerative colitis; inflammatory joint diseases such as gout, pseudogout, arthropathy, osteoarthritis, and rheumatoid arthritis; further rheumatic diseases such as dermatomyositis, Still's disease, and juvenile idiopathic arthritis; kidney-related diseases such as hyperoxaluria, lupus nephritis, hypertensive nephropathy, hemodialysis-associated inflammation, diabetic nephropathy, and diabetic kidney disease; and other inflammatory diseases (Miyamae T. Paediatr Drugs, 2012 Apr 1, 14(2): 109-17;Szabo G and Petrasek J. Nat Rev Gastroenterol Hepatol, 2015 Jul;12(7):387-400;Zhen Y and Zhang H. Front Immunol, 2019 Feb 28;10:276;Vande Walle Let al., Nature, 2014 Aug 7;512(7512):69-73;Knauf et al., Kidney Int, 2013 Nov;84(5):895-901;Krishnan et al., Br J Pharmacol, 2016 Feb;l 73(4):752-65);Shahzad et al., Kidney Int, 2015 Jan;87(1):74-84;Jankovic, et al. J Exp Med. 2013 Sep 23;210(10):1899-910). Activation of the NLRP3 inflammasome has also been associated with brain infections, acute injury, neuroinflammatory disorders such as multiple sclerosis and amyotrophic lateral sclerosis, and the onset and progression of neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease (Sarkar et al., NPJ Parkinsons Dis, 2017 Oct 17;3:30).

[0007] Cardiovascular and metabolic diseases, such as atherosclerosis, type I and type II diabetes, and diabetic complications, such as nephropathy and retinopathy, peripheral arterial disease, acute heart failure, and hypertension, have been linked to NLRP3 (Ridker et al., CANTOS Trial Group. N Engl J Med, 2017 Sep 21;377(12):1119-1131; and Toldo S and Abbate A Nat Rev Cardiol, 2018 Apr;15(4):203-214). NLRP3-associated skin diseases include wound healing and scar formation; inflammatory skin diseases, such as acne, atopic dermatitis, hidradenitis suppurativa, and psoriasis (Kelly et al., Br J Dermatol, 2015 Dec;1 73(6)). NLRP3 inflammasome activity has also been implicated in respiratory diseases such as asthma, sarcoidosis, acute respiratory distress syndrome, and severe acute respiratory syndrome (SARS) (Nieto-Torres et al., Virology, 2015 Nov;485:330-9)); and ocular diseases such as age-related macular degeneration (AMD) and diabetic retinopathy (Doyle et al., Nat Med, 2012 May;18(5):791-8). NLRP3-associated cancers include myeloproliferative neoplasms, leukemia, myelodysplastic syndromes, myelofibrosis, lung cancer, and colorectal cancer (Ridker et al., Lancet, 2017 Oct 21;390(10105): 1833-1842; Derangere et al., Cell Death Differ. 2014 Dec;21(12): 1914-24; Basiorka et al., Lancet Haematol, 2018 Sep;5(9): e393-e402, Zhang et al., Hum Immunol, 2018 Jan;79(1):57-62).

[0008] Immune and inflammatory diseases are typically difficult to diagnose and treat efficiently and effectively, and most treatments involve treating symptoms, slowing disease progression, lifestyle changes, and surgery.

[0009] There remains a need for inhibitors of NLRP3 to provide new therapies for diseases and disorders associated with NLRP3 inflammasome activation and dysregulation. Compounds of structural formula I are useful for treating and preventing diseases, disorders, and conditions mediated by NLRP3 inflammasome formation and proliferation.

[0010] NLRP3 inhibitors are disclosed in the following publications: Nat. 2022, 1; Cell. 2021, 184, 1; J. Mol. Biol. 2021, 433, 167308; J. Med. Chem. 2021, 64, 101; Nat. Chem. Biol. 2019, 15, 556; Nat. 2019, 570, 338; Nat. Chem. Biol. 2019, 15, 560; PLOS Biol. 2019, 1; Nat. Med. 2015, 21, 248; Cell. 2014, 156, 1193; Nat. Immunol. 2014, 15, 738; PNAS. 2007, 104, 8041; Nat. 2006, 440, 9; Immunity. 2006, 24, 317.Several patent applications describe NLRP3 inhibitors, including: WO 2021 / 239885, WO 2021 / 209552, WO 2021 / 209539, WO 2021 / 193897, WO 2020 / 018975, WO 2020 / 037116, WO 2020 / 021447, WO 2020 / 010143, WO 2019 / 079119, WO 2019 / 0166621, WO 2019 / 121691, WO 2019 / 034696, WO 2019 / 034697, WO 2019 / 034693, WO 2019 / 034692, WO 2019 / 034690, WO 2019 / 034688, WO 2019 / 034686, WO 2019 / 008025, WO 2019 / 008029, WO 2019 / 023145, WO 2019 / 023147, WO 2019 / 025467, WO 2018 / 167468, WO 2018 / 015445, WO 2017 / 184746, WO 2017 / 184735, WO 2017 / 184623, WO 2017 / 184604, WO 2017 / 184624, WO 2017 / 140778, WO 2016 / 131098, US 11,319,319, US 2020 / 0361898, WO 2023 / 032987, WO 2023 / 032987, WO 2022 / 230912, WO 2023 / 275366, WO 2022 / 237781, WO 2022 / 036204, WO 2023 / 288039, WO 2022 / 204227, WO 2022 / 229315, WO 2022 / 184843, WO 2022 / 184842, WO 2022 / 063896, WO 2022 / 063876, WO 2021 / 219784, WO 2023 / 032987, WO 2022 / 166890, WO 2023 / 028534, WO 2023 / 028536, WO 2022 / 238347, WO 2022 / 253936, WO 2022 / 253326, WO 2022 / 135567, WO 2023 / 278438, and US 11,618,751. [Prior art documents] [Patent documents]

[0011] [Patent Document 1] WO 2021 / 239885 [Patent Document 2] WO 2021 / 209552 [Patent Document 3] WO 2021 / 209539 [Patent Document 4] WO 2021 / 193897 [Patent Document 5] WO 2020 / 018975 [Patent Document 6] WO 2020 / 037116 [Patent Document 7] WO 2020 / 021447 [Patent Document 8] WO 2020 / 010143 [Patent Document 9] WO 2019 / 079119 [Patent Document 10] WO 2019 / 0166621 [Patent Document 11] WO 2019 / 121691 [Patent Document 12] WO 2019 / 034696 [Patent Document 13] WO 2019 / 034697 [Patent Document 14] WO 2019 / 034693 [Patent Document 15] WO 2019 / 034692 [Patent Document 16] WO 2019 / 034690 [Patent Document 17] WO 2019 / 034688 [Patent Document 18] WO 2019 / 034686 [Patent Document 19] WO 2019 / 008025 [Patent Document 20] WO 2019 / 008029 [Patent Document 21] WO 2019 / 023145 [Patent Document 22] WO 2019 / 023147 [Patent Document 23] WO 2019 / 025467 [Patent Document 24] WO 2018 / 167468 [Patent Document 25] WO 2018 / 015445 [Patent Document 26] WO 2017 / 184746 [Patent Document 27] WO 2017 / 184735 [Patent Document 28] WO 2017 / 184623 [Patent Document 29] WO 2017 / 184604 [Patent Document 30] WO 2017 / 184624 [Patent Document 31] WO 2017 / 140778 [Patent Document 32] WO 2016 / 131098 [Patent Document 33] US 11,319,319 [Patent Document 34] US 2020 / 0361898 [Patent Document 35] WO 2023 / 032987 [Patent Document 36] WO 2023 / 032987 [Patent Document 37] WO 2022 / 230912 [Patent Document 38] WO 2023 / 275366 [Patent Document 39] WO 2022 / 237781 [Patent Document 40] WO 2022 / 036204 [Patent Document 41] WO 2023 / 288039 [Patent Document 42] WO 2022 / 204227 [Patent Document 43] WO 2022 / 229315 [Patent Document 44] WO 2022 / 184843 [Patent Document 45] WO 2022 / 184842 [Patent Document 46] WO 2022 / 063896 [Patent Document 47] WO 2022 / 063876 [Patent Document 48] WO 2021 / 219784 [Patent Document 49] WO 2023 / 032987 [Patent Document 50] WO 2022 / 166890 [Patent Document 51] WO 2023 / 028534 [Patent Document 52] WO 2023 / 028536 [Patent Document 53] WO 2022 / 238347 [Patent Document 54] WO 2022 / 253936 [Patent Document 55] WO 2022 / 253326 [Patent Document 56] WO 2022 / 135567 [Patent Document 57] WO 2023 / 278438 [Patent Document 58] US 11,618,751 [Non-patent literature]

[0012] [Non-Patent Document 1] Van Opdenbosch N and Lamkanfi M. Immunity, 2019 Jun 18;50(6):1352-1364 [Non-patent document 2] Tartey S and Kanneganti TD. Immunology, 2019 Apr;l56(4):329-338 [Non-licensed document 3] Kelley et al., Int J Mol Sci, 2019 Jul 6;20(13)

Non-licensed Document 4

Non-licensed Document 5

Non-licensed Document 6

Non-licensed Document 7

Non-licensed Document 8

Non-licensed literature 9

Non-licensed literature 10

Non-licensed Document 11

Non-licensed Document 12

Non-licensed Document 13

[0013] The present disclosure provides compounds of structural formula I: [ka] and pharmaceutically acceptable salts, hydrates and solvates thereof.

[0014] Compounds of structural formula I and embodiments thereof are inhibitors of NOD-like receptor protein 3 (NLRP3) and may be useful in the treatment and prevention of NLRP3-mediated diseases, disorders, and conditions, such as, but not limited to, gout, pseudogout (chondrocalcinosis), cryopyrin-associated periodic syndromes (CAPS), NASH, fibrosis, heart failure, idiopathic pericarditis, atopic dermatitis, inflammatory bowel disease, Alzheimer's disease, Parkinson's disease, and traumatic brain injury. The present disclosure further relates to pharmaceutical compositions comprising a compound of structural formula I, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and a pharmaceutically acceptable carrier.

[0015] Also disclosed are methods of treating, managing, preventing, alleviating, ameliorating, suppressing or controlling disorders, diseases and symptoms responsive to inhibition of the NLRP3 receptor in a subject in need thereof, wherein the methods are by administering the compounds and pharmaceutical compositions of the present disclosure.

[0016] The present disclosure further relates to the use of compounds of structural formula I for the manufacture of a medicament useful in the treatment of diseases, disorders, and conditions responsive to inhibition of the NLRP3 receptor.

[0017] The present disclosure further relates to methods of treating or preventing these diseases, disorders, and conditions by administering a compound of structural formula I in combination with a therapeutically effective amount of another agent that may be useful in treating these diseases, disorders, and conditions. The present disclosure also relates to processes for preparing compounds of structural formula I. DETAILED DESCRIPTION OF THE INVENTION

[0018] The present disclosure provides compounds of structural formula I: [ka] [During the ceremony, X is (1)=C(R 4 )-, and, (2)=N- are independently selected from the group R 1 teeth, (1)-C 3-12 cycloalkyl, (2)-C 3-12 cycloalkenyl, (3)-C 2-11 cycloheteroalkyl, (4)-C 2-11 cycloheteroalkenyl, (5) aryl, (6) heteroaryl, (7)-C 1-6 Alkyl, (8)-C 1-6 alkyl-OH, (9)-C 1-6 Alkyl-C 3-12 cycloalkyl, (10)-C 1-6 Alkyl-C 3-12 cycloalkenyl, (11)-C 1-6 Alkyl-C 2-11 cycloheteroalkyl, (12)-C 1-6 Alkyl-C 2-11 cycloheteroalkenyl, (13)-C 1-6 Alkyl-aryl, and (14)-C 1-6 Alkyl-Heteroaryl where R 1 is unsubstituted or R a and is substituted with 1 to 6 substituents selected from: R2 teeth, (1) Hydrogen, (2)CN, (3)-CF3, (4)-CHF2, (5)-C 1-6 Alkyl, and (6) Halogen wherein alkyl is unsubstituted or selected from the group of R b and is substituted with 1 to 5 substituents selected from: R 3 teeth, (1) aryl, and (2) Heteroaryl wherein aryl and heteroaryl are unsubstituted or selected from the group consisting of R c and is substituted with 1 to 5 substituents selected from: R 4 teeth, (1) Hydrogen, (2)CN, (3)-C 1-6 Alkyl, (4)-OC 1-6 Alkyl, and (5) Halogen wherein each alkyl is unsubstituted or selected from the group of R d and is substituted with 1 to 5 substituents selected from: R 5 teeth, (1) Hydrogen, (2)CN, (3)-C 1-6 Alkyl, (4)-OC 1-6 Alkyl, and (5) Halogen wherein each alkyl is unsubstituted or selected from the group of R e and is substituted with 1 to 5 substituents selected from: Each R a teeth, (1)CN, (2) oxo, (3)-OH, (4) halogens, (5)-C 1-6 Alkyl, (6)-C 1-6 alkyl-OH, (7)-OC 1-6 Alkyl, (8)-C 3-6 cycloalkyl, (9)-C 2-6 cycloheteroalkyl, (10) aryl, (11) heteroaryl, (12)-C(O)C 1-6 Alkyl, (13)-C(O)C 3-6 cycloalkyl, (14)-C 1-6 Alkyl-aryl, (15)-C 1-6 alkyl-heteroaryl, (16)-C 1-6 Alkyl-C 3-6 cycloalkyl, (17)-C 1-6 Alkyl-C 2-6 cycloheteroalkyl, (18)-(CH2) p -OC 1-6 Alkyl, (19)-(CH2) p -OC 3-6 cycloalkyl, (20)-(CH2) p -OC 2-6 cycloheteroalkyl, (21)-(CH2) p -O-aryl, (22)-(CH2) p -O-heteroaryl, (23)-(CH2) p -S(O) r R f , and (24)-N(R g )2 where each R a is unsubstituted or is substituted with halogen, CF3, OH, C1-6 Alkyl and -OC 1-6 substituted with 1 to 6 substituents selected from alkyl; Each R b teeth, (1) CF3, (2) halogens, (3)-C 1-6 Alkyl, and (4)-C 3-6 cycloalkyl are independently selected from the group Each R c teeth, (1)CN, (2)-OH, (3) oxo, (4) halogens, (5)-C 1-6 Alkyl, (6)-OC 1-6 Alkyl, (7)-C 3-6 cycloalkyl, (8)-C 2-6 cycloheteroalkyl, (9) aryl, (10) heteroaryl, (11)-C 1-6 Alkyl-aryl, (12)-C 1-6 alkyl-heteroaryl, (13)-C 1-6 Alkyl-C 3-6 cycloalkyl, (14)-C 1-6 Alkyl-C 2-6 cycloheteroalkyl, (15)-(CH2) q -OC 1-6 Alkyl, (16)-(CH2) q -OC 3-6 cycloalkyl, (17)-(CH2) q -OC 2-6 cycloheteroalkyl, (18)-(CH2) q -O-aryl, (19)-(CH2) q -O-heteroaryl, (20)-OC 1-6 Alkyl-C 3-6 cycloalkyl, (21)-OC 1-6 Alkyl-C 2-6 cycloheteroalkyl, (22)-OC 1-6 Alkyl-aryl, (23)-OC 1-6 alkyl-heteroaryl, (24)-(CH2) q -S(O) r R h , (25)-N(R i )2, (26)-C(O)R j , and (27)-C(O)NR i where each R c is unsubstituted or is a halogen, CF3, CF2H, OCF3, CN, CH2CF3, CF2CH3, -C 1-6 Alkyl and -OC 1-6 substituted with 1 to 6 substituents selected from alkyl; Each R d teeth, (1) Hydrogen, (2)OH, (3) halogens, and (4)-C 1-6 Alkyl are independently selected from the group Each R e teeth, (1) Hydrogen, (2)OH, (3) halogens, and (4)-C 1-6 Alkyl are independently selected from the group Each R f teeth, (1) Hydrogen, (2)-C 1-6 Alkyl, (3)-C3-6 cycloalkyl, and (4)-C 2-6 cycloheteroalkyl are independently selected from the group Each R g teeth, (1) Hydrogen, (2)-C 1-6 Alkyl, (3)-C 3-6 cycloalkyl, (4)-C 2-6 cycloheteroalkyl, (5) aryl, (6) heteroaryl, (7)-C(O)C 1-6 Alkyl, and (8)-S(O) r R f wherein alkyl is unsubstituted or selected from the group consisting of CF3, halogen, OH and -OC. 1-6 may be substituted with 1 to 3 substituents selected from alkyl; Each R h teeth, (1) Hydrogen, (2)-C 1-6 Alkyl, (3)-C 3-6 cycloalkyl, and (4)-C 2-6 cycloheteroalkyl are independently selected from the group Each R i teeth, (1) Hydrogen, (2)-C 1-6 Alkyl, (3)-C 3-6 cycloalkyl, and (4)-C 2-6 cycloheteroalkyl are independently selected from the group Each R j teeth, (1)OH, (2)-C 1-6 Alkyl, (3)-C3-6 cycloalkyl, and (4)-C 2-6 cycloheteroalkyl wherein alkyl is unsubstituted or selected from the group consisting of CF3, halogen, OH and -OC. 1-6 may be substituted with 1 to 3 substituents selected from alkyl; p is 0, 1, 2, 3, 4, 5 or 6; q is 0, 1, 2, 3, 4, 5 or 6; and r is 1 or 2. and pharmaceutically acceptable salts, hydrates and solvates thereof.

[0019] The present disclosure has many embodiments, which are summarized below: The present disclosure includes the compounds shown and also includes the individual diastereoisomers, enantiomers, and epimers of the compounds, as well as mixtures of the diastereoisomers and / or enantiomers, including racemic mixtures.

[0020] In another embodiment of the present invention, X is ═C(R 4 )- and ═N-. In one class of this embodiment, X is independently selected from the group: ═C(R 4 )-. In another class of this embodiment, X is =N-.

[0021] In one embodiment, R 1 -C 3-12 Cycloalkyl, -C 3-12 Cycloalkenyl, -C 2-11 Cycloheteroalkyl, -C 2-11 Cycloheteroalkenyl, aryl, heteroaryl, -C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-C 3-12 Cycloalkyl, -C 1-6 Alkyl-C 3-12 Cycloalkenyl, -C 1-6 Alkyl-C2-11 Cycloheteroalkyl, -C 1-6 Alkyl-C 2-11 cycloheteroalkenyl, -C 1-6 Alkyl-aryl and -C 1-6 alkyl-heteroaryl, wherein R 1 is unsubstituted or R a is substituted with 1 to 6 substituents selected from:

[0022] In another embodiment, R 1 -C 3-12 Cycloalkyl, -C 2-11 Cycloheteroalkyl, aryl, heteroaryl, -C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-C 3-12 Cycloalkyl, -C 1-6 Alkyl-C 2-11 Cycloheteroalkyl, -C 1-6 Alkyl-aryl and -C 1-6 alkyl-heteroaryl, wherein R 1 is unsubstituted or R a is substituted with 1 to 6 substituents selected from:

[0023] In another embodiment, R 1 -C 3-12 Cycloalkyl, -C 2-11 Cycloheteroalkyl, aryl, heteroaryl, -C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-C 3-12 Cycloalkyl and -C 1-6 Alkyl-C 2-11 cycloheteroalkyl, wherein R 1 is unsubstituted or R a is substituted with 1 to 6 substituents selected from:

[0024] In another embodiment, R 1 -C3-12 Cycloalkyl, -C 2-11 Cycloheteroalkyl, heteroaryl, -C 1-6 Alkyl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-C 3-12 Cycloalkyl and -C 1-6 Alkyl-C 2-11 cycloheteroalkyl, wherein R 1 is unsubstituted or R a is substituted with 1 to 6 substituents selected from:

[0025] In another embodiment, R 1 -C 3-12 Cycloalkyl, -C 2-11 Cycloheteroalkyl, heteroaryl, -C 1-6 Alkyl-OH, -C 1-6 Alkyl-C 3-12 Cycloalkyl and -C 1-6 Alkyl-C 2-11 cycloheteroalkyl, wherein R 1 is unsubstituted or R a is substituted with 1 to 6 substituents selected from:

[0026] In another embodiment, R 1 -C 3-12 Cycloalkyl, -C 2-11 Cycloheteroalkyl, -C 1-6 Alkyl-C 3-12 Cycloalkyl and -C 1-6 Alkyl-C 2-11 cycloheteroalkyl, wherein R 1 is unsubstituted or R a is substituted with 1 to 6 substituents selected from:

[0027] In another embodiment, R 1 -C 3-12 Cycloalkyl and -C 2-11 cycloheteroalkyl, wherein R 1is unsubstituted or R a In one class of this embodiment, R 1 is selected from the group of bicyclo[3.1.1]heptane, piperidine, 8-azabicyclo[3.2.1]octane, and octahydroindolizine, wherein R 1 is unsubstituted or R a is substituted with 1 to 6 substituents selected from:

[0028] In another embodiment, R 1 -C 3-12 cycloalkyl, where R 1 is unsubstituted or R a In one class of this embodiment, R 1 is a bicyclo[3.1.1]heptane, where the bicyclo[3.1.1]heptane is unsubstituted or a is substituted with 1 to 6 substituents selected from:

[0029] In another embodiment, R 1 is C 2-11 cycloheteroalkyl, where cycloheteroalkyl is unsubstituted or R a In one class of this embodiment, R 1 is piperidine, where piperidine is unsubstituted or R a In another class of this embodiment, R 1 is selected from the group of piperidine, 8-azabicyclo[3.2.1]octane, and octahydroindolizine, wherein R 1 is unsubstituted or R a is substituted with 1 to 6 substituents selected from:

[0030] In another embodiment, R 2 is hydrogen, CN, -CF3, -CHF2, -C1-6 alkyl and halogen, where R 2 is unsubstituted or R b In one class of this embodiment, R 2 is hydrogen and -C 1-6 alkyl, wherein alkyl is unsubstituted or R b In a subclass of this class, R 2 is hydrogen or -CH3, where -CH3 is unsubstituted or b In another class of this embodiment, R 2 -C 1-6 alkyl, where R 2 is unsubstituted or R b In a subclass of this class, R 2 is -CH3, where R 2 is unsubstituted or R b In another class of this embodiment, R 2 is hydrogen.

[0031] In another embodiment of the present invention, R 3 is selected from the group of aryl and heteroaryl, where R 3 is unsubstituted or R c In one class of this embodiment, R 3 is selected from the group of phenyl, benzothiophene and indane, where R 3 is unsubstituted or R c is substituted with 1 to 5 substituents selected from:

[0032] In another embodiment, R 3 is heteroaryl, where heteroaryl is unsubstituted or cIn one class of this embodiment, R 3 is benzothiophene, where R 3 is unsubstituted or R c is substituted with 1 to 5 substituents selected from:

[0033] In another embodiment, R 3 is aryl, where aryl is unsubstituted or R c In one class of this embodiment, R 3 is phenyl or indan, where R 3 is unsubstituted or R c In another class of this embodiment, R 3 is phenyl, where phenyl is unsubstituted or R c In another class of this embodiment, R 3 is an indane, where the indane is unsubstituted or c is substituted with 1 to 5 substituents selected from:

[0034] In another embodiment of the present invention, R 4 is hydrogen, CN, -C 1-6 Alkyl, -OC 1-6 alkyl and halogen, wherein each alkyl is unsubstituted or selected from the group consisting of R d is substituted with 1 to 5 substituents selected from:

[0035] In another embodiment of the present invention, R 4 is hydrogen or -C 1-6 alkyl, where each alkyl is unsubstituted or R d is substituted with 1 to 5 substituents selected from:

[0036] In another embodiment of the present invention, R 4-C 1-6 alkyl, where each alkyl is unsubstituted or R d is substituted with 1 to 5 substituents selected from:

[0037] In another embodiment of the present invention, R 4 is hydrogen.

[0038] In another embodiment of the present invention, R 5 is hydrogen, CN, -C 1-6 Alkyl, -OC 1-6 alkyl and halogen, wherein each alkyl is unsubstituted or selected from the group consisting of R e is substituted with 1 to 5 substituents selected from:

[0039] In another embodiment of the present invention, R 5 is hydrogen, CN, -C 1-6 Alkyl, -OC 1-6 alkyl and halogen, wherein each alkyl is unsubstituted or selected from the group consisting of R e is substituted with 1 to 5 substituents selected from:

[0040] In another embodiment of the present invention, R 5 is hydrogen or -C 1-6 alkyl, where each alkyl is unsubstituted or R e In one class of this embodiment, R 5 is hydrogen or -CH3.

[0041] In another embodiment of the present invention, R 5 -C 1-6 alkyl, where each alkyl is unsubstituted or R e In one class of this embodiment, R 5 is -CH3.

[0042] In another embodiment of the present invention, R 5is hydrogen.

[0043] In another embodiment, each R a is CN, oxo, -OH, halogen, -C 1-6 Alkyl, -C 1-6 Alkyl-OH, -OC 1-6 Alkyl, -C 3-6 Cycloalkyl, -C 2-6 Cycloheteroalkyl, aryl, heteroaryl, -C(O)C 1-6 Alkyl, -C(O)C 3-6 Cycloalkyl, -C 1-6 Alkyl-aryl, -C 1-6 Alkyl-heteroaryl, -C 1-6 Alkyl-C 3-6 Cycloalkyl, -C 1-6 Alkyl-C 2-6 Cycloheteroalkyl, -(CH2) p -OC 1-6 Alkyl, -(CH2) p -OC 3-6 Cycloalkyl, -(CH2) p -OC 2-6 Cycloheteroalkyl, -(CH2) p -O-aryl, -(CH2) p -O-heteroaryl, -(CH2) p -S(O) r R f and -N(R g )2, wherein each R a is unsubstituted or is substituted with halogen, CF3, OH, C 1-6 Alkyl and -OC 1-6 and substituted with 1 to 6 substituents selected from alkyl.

[0044] In another embodiment, each R a is CN, oxo, -OH, halogen, -C 1-6 Alkyl, -C 1-6 Alkyl-OH, -OC 1-6 Alkyl, -C 3-6 Cycloalkyl, -C 2-6 Cycloheteroalkyl, aryl, heteroaryl, -C1-6 Alkyl-aryl, -C 1-6 Alkyl-heteroaryl, -C 1-6 Alkyl-C 3-6 Cycloalkyl, -C 1-6 Alkyl-C 2-6 Cycloheteroalkyl, -(CH2) p -S(O) r R f and -N(R g )2, wherein each R a is unsubstituted or is substituted with halogen, CF3, OH, C 1-6 Alkyl and -OC 1-6 and substituted with 1 to 6 substituents selected from alkyl.

[0045] In another embodiment, each R a is CN, oxo, -OH, halogen, -C 1-6 Alkyl, -C 1-6 Alkyl-OH, -OC 1-6 Alkyl, -C 3-6 Cycloalkyl, -C 2-6 Cycloheteroalkyl, -C 1-6 Alkyl-C 3-6 Cycloalkyl, -C 1-6 Alkyl-C 2-6 Cycloheteroalkyl, -(CH2) p -S(O) r R f and -N(R g )2, wherein each CH2, alkyl, cycloalkyl, and cycloheteroalkyl is independently unsubstituted or substituted with halogen, CF3, OH, C 1-6 Alkyl and -OC 1-6 and substituted with 1 to 6 substituents selected from alkyl.

[0046] In another embodiment, each R a is CN, oxo, -OH, halogen, -C 1-6 Alkyl, -C 1-6 Alkyl-OH, -OC 1-6 Alkyl, -C 3-6 Cycloalkyl, -C2-6 Cycloheteroalkyl, aryl, heteroaryl, -C 1-6 Alkyl-C 3-6 Cycloalkyl, -C 1-6 Alkyl-C 2-6 Cycloheteroalkyl, -(CH2) p -S(O) r R f and -N(R g )2, wherein each CH2, alkyl, cycloalkyl, and cycloheteroalkyl is independently unsubstituted or substituted with halogen, CF3, OH, C 1-6 Alkyl and -OC 1-6 and substituted with 1 to 6 substituents selected from alkyl.

[0047] In another embodiment, each R a is CN, oxo, -OH, halogen, -C 1-6 Alkyl, -C 1-6 Alkyl-OH, -OC 1-6 Alkyl, -C 3-6 Cycloalkyl, -C 2-6 Cycloheteroalkyl, aryl, heteroaryl, -C 1-6 Alkyl-C 3-6 Cycloalkyl and -C 1-6 Alkyl-C 2-6 and cycloheteroalkyl, wherein each CH, alkyl, cycloalkyl, and cycloheteroalkyl is independently unsubstituted or substituted with halogen, CF, OH, C 1-6 Alkyl and -OC 1-6 and substituted with 1 to 6 substituents selected from alkyl.

[0048] In another embodiment, each R a is CN, oxo, -OH, halogen, -C 1-6 Alkyl, -C 1-6 Alkyl-OH, -OC 1-6 Alkyl, -C 3-6 Cycloalkyl, -C 1-6 Alkyl-C 3-6 Cycloalkyl, -(CH2) p-S(O) r R f and -N(R g )2, wherein each CH2, alkyl, and cycloalkyl is independently unsubstituted or selected from the group consisting of halogen, CF3, OH, C 1-6 Alkyl and -OC 1-6 and substituted with 1 to 6 substituents selected from alkyl.

[0049] In another embodiment, each R a is CN, oxo, -OH, halogen, -C 1-6 Alkyl, -C 1-6 Alkyl-OH, -OC 1-6 Alkyl, -C 3-6 Cycloalkyl and -C 1-6 Alkyl-C 3-6 and cycloalkyl, wherein each CH, alkyl, and cycloalkyl is independently unsubstituted or substituted with halogen, CF, OH, C 1-6 Alkyl and -OC 1-6 and substituted with 1 to 6 substituents selected from alkyl.

[0050] In another embodiment, each R a -OH, -C 1-6 Alkyl and -C 3-6 and cycloalkyl, wherein each alkyl and cycloalkyl is independently unsubstituted or substituted with halogen, CF, OH, C 1-6 Alkyl and -OC 1-6 In one class of this embodiment, each R is substituted with 1 to 6 substituents selected from alkyl, a is independently selected from the group: -OH, -CH3, -CD3, -CH2CH3, -CH(CH3)2, and cyclobutyl. In another class of this embodiment, each R a is independently selected from the group: -OH, -CH3, -CH2CH3, -CH(CH3)2, and cyclobutyl. In another class of this embodiment, each R ais independently selected from the group: -OH, -CH3, -CD3, -CH2CH3, and -CH(CH3)2. In another class of this embodiment, each R a are independently selected from the group of -OH, -CH3, -CH2CH3, and -CH(CH3)2.

[0051] In another embodiment, each R a is -OH or -C 1-6 alkyl, where each alkyl is unsubstituted or substituted with halogen, CF, OH, C 1-6 Alkyl and -OC 1-6 In one class of this embodiment, each R is substituted with 1 to 6 substituents selected from alkyl, a are independently selected from the group of -OH, -CH3, and -CH2CH3.

[0052] In another embodiment, each R a is -OH.

[0053] In another embodiment, each R a -C 1-6 alkyl, where each alkyl is unsubstituted or substituted with halogen, CF, OH, C 1-6 Alkyl and -OC 1-6 In one class of this embodiment, each R is substituted with 1 to 6 substituents selected from alkyl, a is -CH3 or -CH2CH3.

[0054] In another embodiment of the present invention, each R b CF3, halogen, -C 1-6 Alkyl and -C 3-6 In one class of this embodiment, each R b CF3, halogens and -C 1-6 In another class of this embodiment, each R b In another class of this embodiment, each R b is halogen. In another class of this embodiment, each R b-C 1-6 It is alkyl.

[0055] In another embodiment of the present invention, each R c is CN, -OH, oxo, halogen, -C 1-6 Alkyl, -OC 1-6 Alkyl, -C 3-6 Cycloalkyl, -C 2-6 Cycloheteroalkyl, aryl, heteroaryl, -C 1-6 Alkyl-aryl, -C 1-6 Alkyl-heteroaryl, -C 1-6 Alkyl-C 3-6 Cycloalkyl, -C 1-6 Alkyl-C 2-6 Cycloheteroaryl, -(CH2) q -OC 1-6 Alkyl, -(CH2) q -OC 3-6 Cycloalkyl, -(CH2) q -OC 2-6 Cycloheteroaryl, -(CH2) q -O-aryl, -(CH2) q -O-heteroaryl, -OC 1-6 Alkyl-C 3-6 Cycloalkyl, -OC 1-6 Alkyl-C 2-6 Cycloheteroalkyl, -OC 1-6 Alkyl-aryl, -OC 1-6 Alkyl-heteroaryl, -(CH2) q -S(O) r R h , -N(R i )2, -C(O)R j and -C(O)NR i where each R c is unsubstituted or is a halogen, CF3, CF2H, OCF3, CN, CH2CF3, CF2CH3, -C 1-6 Alkyl and -OC 1-6 and substituted with 1 to 6 substituents selected from alkyl.

[0056] In another embodiment, each Rc is CN, -OH, oxo, halogen, -C 1-6 Alkyl, -OC 1-6 Alkyl, -C 3-6 Cycloalkyl, -C 2-6 Cycloheteroalkyl, aryl, heteroaryl, -(CH2) q -S(O) r R h , -N(R i )2, -C(O)R j and -C(O)NR i where each R c is unsubstituted or is a halogen, CF3, CF2H, OCF3, CN, CH2CF3, CF2CH3, -C 1-6 Alkyl and -OC 1-6 and substituted with 1 to 6 substituents selected from alkyl.

[0057] In another embodiment, each R c is CN, -OH, oxo, halogen, -C 1-6 Alkyl, -OC 1-6 Alkyl, -(CH2) q -S(O) r R h , -N(R i )2, -C(O)R j and -C(O)NR i wherein each alkyl is unsubstituted or selected from the group consisting of halogen, CF3, CF2H, OCF3, CN, CH2CF3, CF2CH3, -C 1-6 Alkyl and -OC 1-6 and substituted with 1 to 6 substituents selected from alkyl.

[0058] In another embodiment, each R c is CN, -OH, oxo, halogen, -C 1-6 Alkyl, -OC 1-6 Alkyl, -C 3-6 Cycloalkyl and -N(R i )2, wherein each R cis unsubstituted or is a halogen, CF3, CF2H, OCF3, CN, CH2CF3, CF2CH3, -C 1-6 Alkyl and -OC 1-6 In one class of this embodiment, each R is substituted with 1 to 6 substituents selected from alkyl, c is independently selected from the group: -OH, Cl, F, -CH3, -CF3, -OCHF2, cyclopropyl, and NH2. In another class of this embodiment, each R c are independently selected from the group of -OH, Cl, -CH3, -CF3, and -OCHF2.

[0059] In another embodiment, each R c -OH, halogen, -C 1-6 Alkyl, -C 3-6 Cycloalkyl and -N(R i )2, wherein each R c is unsubstituted or is a halogen, CF3, CF2H, OCF3, CN, CH2CF3, CF2CH3, -C 1-6 Alkyl and -OC 1-6 In one class of this embodiment, each R is substituted with 1 to 6 substituents selected from alkyl, c is independently selected from the group: -OH, Cl, F, -CH3, -CF3, -OCHF2, cyclopropyl, and NH2. In another class of this embodiment, each R c are independently selected from the group of -OH, Cl, -CH3, -CF3, and -OCHF2.

[0060] In another embodiment, each R c -OH, halogen, -C 1-6 Alkyl and -OC 1-6 and alkyl, wherein each alkyl is unsubstituted or selected from the group consisting of halogen, CF, CFH, OCF, CN, CHCF, CFCH, -C 1-6 Alkyl and -OC 1-6 In one class of this embodiment, each R is substituted with 1 to 6 substituents selected from alkyl, cis independently selected from the group: -OH, Cl, F, -CH3, -CF3, and -OCHF2. In another class of this embodiment, each R c are independently selected from the group of -OH, Cl, -CH3, -CF3, and -OCHF2.

[0061] In another embodiment, each R c -OH and -C 1-6 and alkyl, wherein each alkyl is unsubstituted or selected from the group consisting of halogen, CF, CFH, OCF, CN, CHCF, CFCH, -C 1-6 Alkyl and -OC 1-6 In one class of this embodiment, each R is substituted with 1 to 6 substituents selected from alkyl, c are independently selected from the group of -OH, -CH3 and -CF3.

[0062] In another embodiment, each R c is independently selected from the group -OH.

[0063] In another embodiment, each R c -C 1-6 and alkyl, wherein each alkyl is unsubstituted or selected from the group consisting of halogen, CF, CFH, OCF, CN, CHCF, CFCH, -C 1-6 Alkyl and -OC 1-6 In one class of this embodiment, each R is substituted with 1 to 6 substituents selected from alkyl, c are independently selected from the group of -OH, -CH3 and -CF3.

[0064] In another embodiment of the present invention, each R d is hydrogen, OH, halogen and -C 1-6 In another embodiment of the present invention, each R d is hydrogen, halogen and -C 1-6 In another embodiment of the present invention, each R d is hydrogen and -C 1-6In one class of this embodiment, each R d -C 1-6 In another class of this embodiment, each R d is hydrogen.

[0065] In another embodiment of the present invention, each R e is hydrogen, OH, halogen and -C 1-6 In another embodiment of the present invention, each R e is hydrogen, halogen and -C 1-6 In another embodiment of the present invention, each R e is hydrogen and -C 1-6 In one class of this embodiment, each R e -C 1-6 In another class of this embodiment, each R e is hydrogen.

[0066] In another embodiment, each R f is hydrogen, -C 1-6 Alkyl, -C 3-6 Cycloalkyl and -C 2-6 In another embodiment, each R f is hydrogen and -C 1-6 In one class of this embodiment, each R f is independently selected from the group hydrogen and CH. In another embodiment, each R f -C 1-6 In one class of this embodiment, each R f is CH3. In another embodiment, each R f is hydrogen.

[0067] In another embodiment of the present invention, each R g is hydrogen, -C 1-6 Alkyl, -C 3-6 Cycloalkyl, -C 2-6 Cycloheteroalkyl, aryl, heteroaryl, -C(O)C1-6 Alkyl and -S(O) r R f wherein alkyl, cycloalkyl, cycloheteroalkyl, aryl, and heteroaryl are unsubstituted or selected from the group consisting of CF, halogen, OH, and —OC. 1-6 In one class of this embodiment, each R g is hydrogen, -C 1-6 Alkyl, -C 3-6 Cycloalkyl, -C 2-6 Cycloheteroalkyl, -C(O)C 1-6 Alkyl and -S(O) r R f wherein alkyl, cycloalkyl, and cycloheteroalkyl are unsubstituted or selected from the group consisting of CF, halogen, OH, and —OC. 1-6 It may be substituted with 1 to 3 substituents selected from alkyl.

[0068] In another embodiment, each R g is hydrogen, -C 1-6 Alkyl, -C(O)C 1-6 Alkyl and -S(O) r R f wherein alkyl is unsubstituted or selected from the group consisting of CF3, halogen, OH and -OC. 1-6 In another embodiment, each R g is hydrogen or -C 1-6 alkyl, where alkyl is unsubstituted or is selected from the group consisting of CF3, halogen, OH and -OC; 1-6 In one class of this embodiment, each R g -C 1-6 alkyl, where alkyl is unsubstituted or is selected from the group consisting of CF3, halogen, OH and -OC; 1-6 In another class of this embodiment, each R g is hydrogen.

[0069] In another embodiment of the present invention, each R h is hydrogen, -C 1-6 Alkyl, -C 3-6 Cycloalkyl and -C 2-6 In another embodiment, each R h is hydrogen and -C 1-6 In one class of this embodiment, each R h is independently selected from the group hydrogen and CH. In another embodiment, each R h -C 1-6 In one class of this embodiment, each R h is CH3. In another embodiment, each R h is hydrogen.

[0070] In another embodiment of the present invention, each R i is hydrogen, -C 1-6 Alkyl, -C 3-6 Cycloalkyl and -C 2-6 In another embodiment, each R i is hydrogen and -C 1-6 In one class of this embodiment, each R i is independently selected from the group hydrogen and CH. In another embodiment, each R i -C 1-6 In one class of this embodiment, each R i is CH3. In another embodiment, each R i is hydrogen.

[0071] In another embodiment of the present invention, each R j -OH, -C 1-6 Alkyl, -C 3-6 Cycloalkyl and -C 2-6 and cycloheteroalkyl, wherein alkyl, cycloalkyl, and cycloheteroalkyl are unsubstituted or selected from the group consisting of CF, halogen, OH, and —OC. 1-6In another embodiment of the present invention, each R j -OH, -C 1-6 Alkyl, -C 3-6 Cycloalkyl and -C 2-6 In another embodiment, each R j -OH and -C 1-6 In one class of this embodiment, each R j is independently selected from the group OH and CH. In another embodiment, each R j -C 1-6 In one class of this embodiment, each R j is CH3. In another embodiment, each R j is OH.

[0072] In another embodiment, p is 0, 1, 2, 3, 4, 5, or 6. In another embodiment, p is 0, 1, 2, 3, 4, or 5. In another embodiment, p is 1, 2, 3, 4, 5, or 6. In another embodiment, p is 1, 2, 3, 4, or 5. In another embodiment, p is 0, 1, 2, 3, or 4. In another embodiment, p is 1, 2, 3, or 4. In another embodiment, p is 0, 1, 2, or 3. In another embodiment, p is 1, 2, or 3. In another embodiment, p is 0, 1, or 2. In another embodiment, p is 1 or 2. In another embodiment, p is 0. In another embodiment, p is 1. In another embodiment, p is 2. In another embodiment, p is 3. In another embodiment, p is 4. In another embodiment, p is 5. In another embodiment, p is 6.

[0073] In another embodiment, q is 0, 1, 2, 3, 4, 5, or 6. In another embodiment, q is 0, 1, 2, 3, 4, or 5. In another embodiment, q is 1, 2, 3, 4, 5, or 6. In another embodiment, q is 1, 2, 3, 4, or 5. In another embodiment, q is 0, 1, 2, 3, or 4. In another embodiment, q is 1, 2, 3, or 4. In another embodiment, q is 0, 1, 2, or 3. In another embodiment, q is 1, 2, or 3. In another embodiment, q is 0, 1, or 2. In another embodiment, q is 1 or 2. In another embodiment, q is 0. In another embodiment, q is 1. In another embodiment, q is 2. In another embodiment, q is 3. In another embodiment, q is 4. In another embodiment, q is 5. In another embodiment, q is 6.

[0074] In another embodiment, r is 1 or 2. In another embodiment, r is 1. In another embodiment, r is 2.

[0075] In another embodiment, the present disclosure provides compounds of structural formula Ia: [ka] or a pharmaceutically acceptable salt, hydrate or solvate thereof.

[0076] In another embodiment, the present disclosure provides compounds of structural formula Ib: [ka] or a pharmaceutically acceptable salt, hydrate or solvate thereof.

[0077] In another embodiment, the present disclosure provides compounds of structural formula Ic: [ka] or a pharmaceutically acceptable salt, hydrate or solvate thereof.

[0078] In another embodiment, the present disclosure provides compounds of structural formula Id: [ka] or a pharmaceutically acceptable salt, hydrate or solvate thereof.

[0079] In another embodiment, the present disclosure provides compounds of structural formula Ie: [ka] or a pharmaceutically acceptable salt, hydrate or solvate thereof.

[0080] Compounds of formula I include compounds of formula Ia, Ib, Ic, Id, and Ie, as well as pharmaceutically acceptable salts, hydrates, and solvates thereof.

[0081] In another embodiment, the present disclosure provides compounds of structural formula I, wherein: X is =C(R 4 )- or =N-; R 1 teeth, (1)-C 3-12 cycloalkyl, (2)-C 2-11 cycloheteroalkyl, (3) heteroaryl, (4)-C 1-6 alkyl-OH, (5)-C 1-6 Alkyl-C 3-12 cycloalkyl, and (6)-C 1-6 Alkyl-C 2-11 cycloheteroalkyl where R 1 is unsubstituted or R a substituted with 1-6 substituents selected from: R 2 is hydrogen and -C 1-6 alkyl, wherein alkyl is unsubstituted or Rb and is substituted with 1 to 5 substituents selected from: R 3 is heteroaryl, where heteroaryl is unsubstituted or c and is substituted with 1 to 5 substituents selected from: R 4 is hydrogen or -C 1-6 alkyl, where each alkyl is unsubstituted or R d and R 5 is hydrogen or -C 1-6 alkyl, where each alkyl is unsubstituted or R e and is substituted with 1 to 5 substituents selected from: and the remaining substituents are as defined above. or a pharmaceutically acceptable salt, hydrate or solvate thereof.

[0082] In another embodiment, the present disclosure provides compounds of structural formula I, wherein: X is =C(R 4 )- or =N-; R 1 is C 2-11 cycloheteroalkyl, where cycloheteroalkyl is unsubstituted or R a and is substituted with 1 to 6 substituents selected from: R 2 is hydrogen and -C 1-6 alkyl, wherein alkyl is unsubstituted or R b and is substituted with 1 to 5 substituents selected from: R 3 is aryl, where aryl is unsubstituted or R c and is substituted with 1 to 5 substituents selected from: R 4 is hydrogen; and R 5 is hydrogen; and the remaining substituents are as defined above. or a pharmaceutically acceptable salt, hydrate or solvate thereof.

[0083] In another embodiment, the present disclosure provides compounds of structural formula I, wherein: X is =N-; R 1 is C 2-11 cycloheteroalkyl, where cycloheteroalkyl is unsubstituted or R a and is substituted with 1 to 6 substituents selected from: R 2 is hydrogen and -C 1-6 alkyl, wherein alkyl is unsubstituted or R b and is substituted with 1 to 5 substituents selected from: R 3 is aryl, where aryl is unsubstituted or R c and is substituted with 1 to 5 substituents selected from: R 4 is hydrogen; and R 5 is hydrogen; and the remaining substituents are as defined above. or a pharmaceutically acceptable salt, hydrate or solvate thereof.

[0084] Illustrative, but non-limiting examples of compounds of the present disclosure useful as inhibitors of NLRP3 are the following compounds: (1) (R)-2-(7-(1-ethylpiperidin-3-yl)-7H-pyrrolo[2,3-c]pyridazin-3-yl)-3-methyl-5-(trifluoromethyl)phenol; (2) (R)-2-(7-(1-ethylpiperidin-3-yl)-4-methyl-7H-pyrrolo[2,3-c]pyridazin-3-yl)-5-(trifluoromethyl)phenol; (3) (R)-2-(7-(1-ethylpiperidin-3-yl)-7H-imidazo[4,5-c]pyridazin-3-yl)-3-methyl-5-(trifluoromethyl)phenol; (4) (R)-3-methyl-2-(7-(1-methylpiperidin-3-yl)-7H-imidazo[4,5-c]pyridazin-3-yl)-5-(trifluoromethyl)phenol; (5) (S)-3-methyl-2-(7-(1-methylpiperidin-3-yl)-7H-imidazo[4,5-c]pyridazin-3-yl)-5-(trifluoromethyl)phenol; (6) (R)-2-(4-methyl-7-(piperidin-3-yl)-7H-imidazo[4,5-c]pyridazin-3-yl)-5-(trifluoromethyl)phenol; (7) (3S,4R)-3-(3-(2-hydroxy-4-(trifluoromethyl)phenyl)-4-methyl-7H-imidazo[4,5-c]pyridazin-7-yl)piperidin-4-ol; (8) (R)-2-(7-(1-ethylpiperidin-3-yl)-4-methyl-7H-imidazo[4,5-c]pyridazin-3-yl)-5-(trifluoromethyl)phenol; (9) (R)-2-(7-(1-methylpiperidin-3-yl)-7H-imidazo[4,5-c]pyridazin-3-yl)-5-(trifluoromethyl)phenol; (10) (S)-2-(7-(1-methylpiperidin-3-yl)-7H-imidazo[4,5-c]pyridazin-3-yl)-5-(trifluoromethyl)phenol; (11) (R)-3-(2-(difluoromethoxy)-4-(trifluoromethyl)phenyl)-7-(1-ethylpiperidin-3-yl)-4-methyl-7H-imidazo[4,5-c]pyridazine; (12) (R)-2-(4-methyl-7-(1-methylpiperidin-3-yl)-7H-imidazo[4,5-c]pyridazin-3-yl)-5-(trifluoromethyl)phenol; (13) (3S,4R)-3-(3-(2-hydroxy-4-(trifluoromethyl)phenyl)-4-methyl-7H-imidazo[4,5-c]pyridazin-7-yl)-1-methylpiperidin-4-ol; and (14) (3S,4R)-1-ethyl-3-(3-(2-hydroxy-4-(trifluoromethyl)phenyl)-4-methyl-7H-imidazo[4,5-c]pyridazin-7-yl)piperidin-4-ol; (15) (R)-5-chloro-2-(4-methyl-7-(piperidin-3-yl)-7H-imidazo[4,5-c]pyridazin-3-yl)phenol; (16) (R)-2-(4,6-dimethyl-7-(1-methylpiperidin-3-yl)-7H-imidazo[4,5-c]pyridazin-3-yl)-5-(trifluoromethyl)phenol; (17) (R)-5-(4-methyl-7-(1-methylpiperidin-3-yl)-7H-imidazo[4,5-c]pyridazin-3-yl)benzo[b]thiophen-4-ol; (18) (R)-5-(4-methyl-7-(1-methylpiperidin-3-yl)-7H-imidazo[4,5-c]pyridazin-3-yl)-2,3-dihydro-1H-inden-4-ol; (19) (R)-5-chloro-2-(4-methyl-7-(1-methylpiperidin-3-yl)-7H-imidazo[4,5-c]pyridazin-3-yl)phenol; and (20) (R)-5-chloro-2-(7-(1-ethylpiperidin-3-yl)-4-methyl-7H-imidazo[4,5-c]pyridazin-3-yl)phenol; Or a pharmaceutically acceptable salt of the above compound.

[0085] Further illustrative, but non-limiting, examples of compounds of the present disclosure useful as inhibitors of NLRP3 are the following compounds: (1) (R)-2-(7-(1-ethylpiperidin-3-yl)-7H-imidazo[4,5-c]pyridazin-3-yl)-3-methyl-5-(trifluoromethyl)phenol; (2) (R)-2-(4-methyl-7-(piperidin-3-yl)-7H-imidazo[4,5-c]pyridazin-3-yl)-5-(trifluoromethyl)phenol; (3) (R)-2-(7-(1-ethylpiperidin-3-yl)-4-methyl-7H-imidazo[4,5-c]pyridazin-3-yl)-5-(trifluoromethyl)phenol; and (4) (R)-2-(4-methyl-7-(1-methylpiperidin-3-yl)-7H-imidazo[4,5-c]pyridazin-3-yl)-5-(trifluoromethyl)phenol; Or a pharmaceutically acceptable salt of the above compound.

[0086] While the specific stereochemistry described above is preferred, other stereoisomers, including diastereoisomers, enantiomers, epimers, and mixtures thereof, may have utility in treating NLRP3-mediated diseases.

[0087] Synthetic methods for preparing the compounds are disclosed in the examples below. Where synthetic details are not described in the examples, the compounds can be readily prepared by those skilled in the art of medicinal chemistry or synthetic organic chemistry by applying the synthetic information provided herein. Where a stereochemical center is not defined, the structure represents a mixture of stereoisomers at that center. For such compounds, individual stereoisomers, including enantiomers and diastereoisomers, and mixtures thereof, are also compounds of the present disclosure.

[0088] definition "Ac" is acetyl, which is CH3C(=O)-.

[0089] "Alkyl" means saturated carbon chains which can be linear or branched or combinations thereof, unless the carbon chain is defined otherwise. Other groups having the prefix "alk," such as alkoxy and alkanoyl, can also be linear or branched or combinations thereof, unless the carbon chain is defined otherwise. Examples of alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, sec- and tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl, and the like. In one embodiment, alkyl is methyl or ethyl. In another embodiment, alkyl is methyl. In another embodiment, alkyl is ethyl.

[0090] "Alkenyl," unless otherwise defined, means carbon chains which contain at least one carbon-carbon double bond, and which may be linear or branched or combinations thereof. Examples of alkenyl include vinyl, allyl, isopropenyl, pentenyl, hexenyl, heptenyl, 1-propenyl, 2-butenyl, 2-methyl-2-butenyl, and the like.

[0091] "Alkynyl," unless otherwise defined, means carbon chains which contain at least one carbon-carbon triple bond, and which may be linear or branched or combinations thereof. Examples of alkynyl include ethynyl, propargyl, 3-methyl-1-pentynyl, 2-heptynyl, and the like.

[0092] "Cycloalkyl" means a saturated monocyclic, bicyclic, spirocyclic, fused or bridged carbocyclic ring having the specified number of carbon atoms. Examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and the like. In one embodiment, cycloalkyl is -C 3-12 It is cycloalkyl.

[0093] "Cycloalkenyl" means a monocyclic, bicyclic, spirocyclic, fused or bridged carbocyclic ring having at least one double bond and having the specified number of carbon atoms. Examples of cycloalkenyl include cyclopropene, cyclobutane, cyclopentene, cyclohexene, cycloheptene, and the like.

[0094] "Cycloheteroalkyl" means a monocyclic, bicyclic, spirocyclic, fused, or bridged ring or ring system having the specified number of carbon atoms and containing at least one saturated ring (wherein at least one ring heteroatom is selected from N, NH, S (including SO and SO), and O) or at least one partially unsaturated ring (wherein at least one ring heteroatom is selected from N, NH, S (including SO and SO), and O). The cycloheteroalkyl ring can be substituted at a ring carbon and / or at a ring nitrogen or ring sulfur. The cycloheteroalkyl ring can be fused to an aryl or heteroaryl ring. Examples of cycloheteroalkyls include tetrahydrofuranyl, pyrrolidinyl, tetrahydrothiophenyl, azetidinyl, piperazinyl, piperidinyl, morpholinyl, oxetanyl, and tetrahydropyranyl. In one embodiment, a cycloheteroalkyl is selected from C 2-11 In another embodiment, C is cycloheteroalkyl. 2-11 The cycloheteroalkyl is piperidine.

[0095] "Cycloheteroalkenyl" means a monocyclic, bicyclic, spirocyclic, fused or bridged ring or ring system having the specified number of carbon atoms and containing at least one double bond and at least one heteroatom selected from N, NH, S (including SO and SO), and O. Examples of cycloheteroalkenyl include dihydropyran and dihydrofuran.

[0096] "Aryl" means a monocyclic, bicyclic, or tricyclic carbocyclic aromatic ring or ring system containing 6 to 14 carbon atoms, wherein at least one of the rings is aromatic. Examples of aryl include phenyl, indane, and naphthalene. In one embodiment, aryl is phenyl. In another embodiment, aryl is indane.

[0097] "Heteroaryl" means a monocyclic, bicyclic, or tricyclic ring or ring system containing from 5 to 14 ring atoms and containing at least one ring heteroatom selected from N, NH, S (including SO and SO), and O, wherein at least one of the heteroatom-containing rings is aromatic. Examples of heteroaryl include pyrrolyl, isoxazolyl, isothiazolyl, pyrazolyl, pyridyl, oxazolyl, oxadiazolyl, thiadiazolyl, thiazolyl, imidazolyl, triazolyl, tetrazolyl, furanyl, triazinyl, thienyl, pyrimidyl, pyridazinyl, pyrazinyl, benzisoxazolyl, benzoxazolyl, benzothiazolyl, benzimidazolyl, benzofuranyl, benzothiophenyl, quinolyl, indolyl, isoquinolyl, quinazolinyl, dibenzofuranyl, and the like.

[0098] "Halogen" includes fluorine, chlorine, bromine, and iodine. In one embodiment, a halogen is fluorine, chorine, or bromine. In another embodiment, a halogen is fluorine or chlorine. In another embodiment, a halogen is chlorine or bromine. In another embodiment, a halogen is fluorine. In another embodiment, a halogen is chlorine. In another embodiment, a halogen is bromine.

[0099] "Me" represents methyl.

[0100] "Oxo" refers to =O.

[0101] "Saturated" means containing only single bonds.

[0102] "Unsaturated" means containing at least one double or triple bond. In one embodiment, "unsaturated" means containing at least one double bond. In another embodiment, "unsaturated" means containing at least one triple bond.

[0103] Variable parts (e.g., R 1 , R a When any variable (e.g., ) occurs more than one time in any constituent or in Structural Formula I, its definition at each occurrence is independent of its definition at every other occurrence. Furthermore, combinations of substituents and / or variables are permissible only if such combinations result in stable compounds. A wavy line across a bond in a substituent variable indicates the point of attachment.

[0104] Under the nomenclature used throughout this disclosure, the point of attachment is described first, followed by the terminal portion of the designated side chain. For example, C 1-5 Alkylcarbonylamino C 1-6 Alkyl substituents are equivalent to the following: [ka]

[0105] In selecting compounds of the present disclosure, one of skill in the art will appreciate the various substituents (i.e., R 1 , R 2 It is recognized that the groups (e.g., aryl, arylsulfonyl ...

[0106] The term "substituted" should be considered to include multiple substitutions by a named substituent. Where multiple substituent moieties are disclosed or claimed, the substituted compound can be independently substituted single or multiple times with one or more of the disclosed or claimed substituent moieties. Independently substituted means that the (two or more) substituents can be the same or different.

[0107] The phrase "pharmaceutically acceptable" is used herein to refer to compounds, materials, compositions, salts and / or dosage forms that are safe and suitable for administration to humans or animals using sound medical judgment and in accordance with all applicable government regulations.

[0108] Compounds of structural formula I may contain one or more asymmetric centers. Accordingly, compounds of structural formula I may occur as racemates and racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers. The present invention is intended to encompass all such isomeric forms of the compounds of structural formula I.

[0109] The independent syntheses of enantiomers and diastereoisomers or their chromatographic separations may be achieved as known in the art by appropriate modification of the methodology disclosed herein. Their absolute stereochemistry may be determined by X-ray crystallography of crystalline products or crystalline intermediates which are derivatized, if necessary, with a reagent containing an asymmetric center of known absolute configuration or with an atom sufficiently heavy to make absolute assignment.

[0110] If necessary, racemic mixtures of the compounds can be separated so that the individual enantiomers are isolated. This separation can be achieved by methods well known in the art, such as coupling a racemic mixture of a compound to an enantiomerically pure compound to form a diastereomeric mixture, followed by separation of the individual diastereoisomers by standard methods such as fractional crystallization or chromatography. The coupling reaction is often the formation of a salt using an enantiomerically pure acid or base. The diastereomeric derivative can then be converted to the pure enantiomer by cleavage of the added chiral residue. Racemic mixtures of the compounds can also be directly separated by chromatographic methods utilizing chiral stationary phases, which are well known in the art.

[0111] Alternatively, any enantiomer of a compound may be obtained by stereoselective synthesis using optically pure starting materials or reagents of known configuration by methods well known in the art.

[0112] Some of the compounds described herein contain olefinic double bonds, and, unless otherwise specified, are meant to include both E and Z geometric isomers.

[0113] Tautomers are defined as compounds that undergo a rapid proton shift from one atom of the compound to another atom of the compound. Some of the compounds described herein may exist as tautomers with different points of attachment of hydrogen. Such an example may be a ketone and its enol form, known as keto-enol tautomers. Individual tautomers and mixtures thereof are encompassed by the compounds represented by structural formula I.

[0114] In compounds of structural formula I, atoms may exhibit their natural isotopic abundance, or one or more of the atoms may be artificially enriched in a particular isotope having the same atomic number but an atomic mass or mass number different from the atomic mass or mass number predominantly found in nature. The present disclosure is intended to encompass all suitable isotopic variations of compounds of structural formula I. For example, different isotopic forms of hydrogen (H) include protium ( 1 H), deuterium ( 2 H or D) and tritium ( 3H). Protium is the predominant hydrogen isotope found in nature. Enrichment with deuterium may offer certain therapeutic advantages, such as increased in vivo half-life or reduced dosage requirements, or may provide compounds useful as standards for characterization of biological samples. Tritium is radioactive and can therefore provide radiolabeled compounds useful as tracers in metabolic or kinetic studies. Isotopically enriched compounds within the scope of structural formula I can be prepared without undue experimentation by conventional techniques well known to those skilled in the art, or by preparative methods similar to those described in the schemes and examples herein using appropriate isotopically enriched reagents and / or intermediates.

[0115] Furthermore, some of the crystalline forms of the compounds of the present disclosure may exist as polymorphs, and as such are intended to be included in the present disclosure. Furthermore, some of the compounds of the present disclosure may form solvates with water or common organic solvents. Such solvates are encompassed within the scope of this invention.

[0116] It is generally preferred to administer the compounds of the present disclosure as enantiomerically pure formulations. Racemic mixtures can be separated into their individual enantiomers by any of a number of conventional methods. These methods include chiral chromatography, derivatization with a chiral auxiliary followed by separation by chromatography or crystallization, and fractional crystallization of diastereomeric salts.

[0117] salt It will be understood that, as used herein, reference to the compounds of the present disclosure is intended to encompass pharmaceutically acceptable salts, and also to encompass salts that are not pharmaceutically acceptable when used as precursors to the free compounds or their pharmaceutically acceptable salts, or in other synthetic operations.

[0118] The compounds of the present disclosure can be administered in the form of pharmaceutically acceptable salts. The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids, including inorganic or organic bases and inorganic or organic acids. The salts of basic compounds encompassed by the term "pharmaceutically acceptable salts" refer to non-toxic salts of the compounds of the present disclosure, which are generally prepared by reacting the free base with a suitable organic or inorganic acid. Representative salts of basic compounds of the present disclosure include, but are not limited to, acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, camsylate, carbonate, chloride, clavulanate, citrate, dihydrochloride, edetate, edisylate, estolate, esylate, formate, fumarate, gluceptate, gluconate, glutamate, glycolyl arsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isopropyl alcohol, and the like. thionate, lactate, lactobionate, laurate, malate, maleate, mandelate, mesylate, methyl bromide, methyl nitrate, methyl sulfate, mucate, napsylate, nitrate, N-methylglucamine ammonium salt, oleate, oxalate, pamoate (embonate), palmitate, pantothenate, phosphate / diphosphate, polygalacturonate, salicylate, stearate, sulfate, acetate, succinate, tannate, tartrate, teoclate, tosylate, triethiodide, trifluoroacetate, and valerate. When the compound of the present disclosure contains an acidic moiety, suitable pharmaceutically acceptable salts thereof include, but are not limited to, salts derived from inorganic bases such as aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganese, manganous, potassium, sodium, zinc, and the like. Particularly preferred are the ammonium, calcium, magnesium, potassium and sodium salts.Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, cyclic amines, and basic ion exchange resins, such as arginine, betaine, caffeine, choline, N,N-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, and the like.

[0119] Furthermore, when a carboxylic acid (—COOH) or alcohol group is present in the compounds of the present disclosure, pharmaceutically acceptable esters of such carboxylic acid derivatives, such as methyl, ethyl, or pivaloyloxymethyl, or acyl derivatives of the alcohol, such as O-acetyl, O-pivaloyl, O-benzoyl, and O-aminoacyl, can also be used. Included are esters and acyl groups known in the art for modifying the solubility or hydrolysis characteristics for use as sustained-release or prodrug formulations.

[0120] The term "prodrug" refers to a compound that is rapidly converted to the parent compound in vivo (e.g., conversion of a prodrug of structural formula I to a compound of structural formula I or a salt thereof), for example, by hydrolysis in blood; a thorough discussion can be found in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems, Vol. 14 of the ACS Symposium Series, and Edward B. Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987, both of which are incorporated herein by reference. The present disclosure encompasses prodrugs of compounds of structural formula I. Solvates, particularly hydrates of compounds of structural formula I, are likewise encompassed by the present disclosure.

[0121] usefulness The compounds of structural formula I are potent inhibitors of Nod-like receptor protein 3 (NLPR3). The compounds of structural formula I and their pharmaceutically acceptable salts, hydrates, and solvates may be effective in treating diseases, disorders, and conditions mediated by inhibition of Nod-like receptor protein 3 (NLPR3).

[0122] The present disclosure relates to the treatment or prevention of an NLRP3-mediated disease, disorder, or condition, such as inflammation, an autoimmune disease, cancer, an infectious disease, a disease or disorder of the central nervous system, a metabolic disease, a cardiovascular disease, a fibrotic disease or fibrosis, a respiratory disease, a kidney disease, a liver disease, an eye or ocular disease, a skin disease, a lymphatic system disease, a rheumatic disease, graft-versus-host disease, allodynia, or an NLRP3-associated disease in a subject determined to have a germline or somatic non-silent mutation in NLRP3.

[0123] NLRP3-mediated diseases, disorders, or conditions include, but are not limited to, gout, pseudogout, osteoarthritis, familial cold autoinflammatory syndrome, Muckle-Wells syndrome, neonatal-onset multisystem inflammatory disease, diabetes, NASH, sepsis, age-related macular degeneration, diabetic retinopathy, liver fibrosis, renal fibrosis, atherosclerosis, heart failure, peripheral arterial disease, myeloproliferative neoplasms, leukemia, myelodysplastic syndromes, myelofibrosis, lung cancer, colorectal cancer, Parkinson's disease, Alzheimer's disease, traumatic brain injury, spinal cord injury, amyotrophic lateral sclerosis, multiple sclerosis, atopic dermatitis, hidradenitis suppurativa, pericarditis, myocarditis, preeclampsia, dermatomyositis, Still's disease, juvenile idiopathic arthritis, age-related macular degeneration, diabetic retinopathy, acute kidney disease, chronic kidney disease, or rare kidney disease. Nod-like receptor protein 3 (NLPR3)-mediated diseases, disorders, or conditions also include gout, pseudogout, CAPS, NASH, fibrosis, osteoarthritis, atherosclerosis, heart failure, idiopathic pericarditis, myocarditis, atopic dermatitis, hidradenitis suppurativa, inflammatory bowel disease, cancer, Alzheimer's disease, Parkinson's disease, and traumatic brain injury.

[0124] In one embodiment, the condition, disease or disorder is an inflammatory joint disease such as gout, pseudogout or osteoarthritis.

[0125] In another embodiment, the cryopyrin-associated periodic syndrome is familial cold autoinflammatory syndrome, Muckle-Wells syndrome, or neonatal-onset multisystem inflammatory disease.

[0126] In another embodiment, the metabolic disease is diabetes.

[0127] In another embodiment, the liver disease is NASH.

[0128] In another embodiment, the infection is sepsis.

[0129] In another embodiment, the eye or eye disease is age-related macular degeneration or diabetic retinopathy.

[0130] In another embodiment, the fibrotic disease is liver fibrosis or kidney fibrosis.

[0131] In some embodiments, the cardiovascular disease is atherosclerosis, heart failure, or peripheral arterial disease.

[0132] In another embodiment, the cancer is a myeloproliferative neoplasm, leukemia, myelodysplastic syndrome, myelofibrosis, lung cancer, or colon cancer.

[0133] In another embodiment, the condition, disease or disorder of the central nervous system is Parkinson's disease, Alzheimer's disease, traumatic brain injury, spinal cord injury, amyotrophic lateral sclerosis or multiple sclerosis.

[0134] In another embodiment, the skin disease is atopic dermatitis or hidradenitis suppurativa (HS).

[0135] In another embodiment, the inflammatory disease is pericarditis or myocarditis.

[0136] In another embodiment, the inflammatory disease is preeclampsia.

[0137] In another embodiment, the rheumatic disease is dermatomyositis, Still's disease, or juvenile idiopathic arthritis.

[0138] In another embodiment, the eye disease is age-related macular degeneration or diabetic retinopathy.

[0139] In another embodiment, the kidney disease is an acute kidney disease, a chronic kidney disease, or a rare kidney disease.

[0140] One or more of these symptoms or diseases can be treated, managed, prevented, alleviated, ameliorated, or controlled by administering a therapeutically effective amount of a compound represented by structural formula I, or a pharmaceutically acceptable salt thereof, to a patient in need of treatment.

[0141] Compounds of structural formula I are further useful in treating these conditions, diseases, or disorders, including, but not limited to, gout, pseudogout, osteoarthritis, familial cold autoinflammatory syndrome, Muckle-Wells syndrome, neonatal-onset multisystem inflammatory disease, diabetes, NASH, sepsis, age-related macular degeneration, diabetic retinopathy, liver fibrosis, kidney fibrosis, atherosclerosis, heart failure, peripheral arterial disease, myeloproliferative neoplasms, leukemia, myelodysplastic syndromes, myelofibrosis, lung cancer, and the like. , colorectal cancer, Parkinson's disease, Alzheimer's disease, traumatic brain injury, spinal cord injury, amyotrophic lateral sclerosis, multiple sclerosis, atopic dermatitis, hidradenitis suppurativa, pericarditis, myocarditis, preeclampsia, dermatomyositis, Still's disease, juvenile idiopathic arthritis, age-related macular degeneration, diabetic retinopathy, acute kidney disease, chronic kidney disease, or rare kidney disease). Compounds of structural formula I can also be used to manufacture medicaments that may be useful in treating, preventing, managing, mitigating, ameliorating, or controlling one or more of these conditions, diseases, or disorders (including, but not limited to, gout, pseudogout, CAPS, NASH, fibrosis, osteoarthritis, atherosclerosis, heart failure, idiopathic pericarditis, myocarditis, atopic dermatitis, hidradenitis suppurativa, inflammatory bowel disease, cancer, Alzheimer's disease, Parkinson's disease, and traumatic brain injury).

[0142] A preferred use of the compound may be for treating one or more of the following diseases by administering a therapeutically effective amount to a patient in need of treatment. The compound can be used to manufacture a medicament for treating one or more of these diseases: (1) Gout, (2) pseudogout, (3) cryopyrin-associated periodic syndrome; (4) nonalcoholic steatohepatitis, (5) fibrosis, (6) osteoarthritis, (7) atherosclerosis, (8) atopic dermatitis, (9) Hidradenitis suppurativa, (10) Alzheimer's disease, and (11) Parkinson's disease.

[0143] Treatment of a disease, disorder, or condition mediated by NLPR3 or the NLPR3 inflammasome pathway refers to the administration of a compound of structural formula I to a subject having the disease, disorder, or condition.

[0144] One outcome of treatment may be alleviating a disease, disorder, or symptom mediated by the NLPR3 or NLPR3 inflammasome pathway. Another outcome of treatment may be alleviating a disease, disorder, or symptom mediated by the NLPR3 or NLPR3 inflammasome pathway. Another outcome of treatment may be ameliorating a disease, disorder, or symptom mediated by the NLPR3 or NLPR3 inflammasome pathway. Another outcome of treatment may be inhibiting a disease, disorder, or symptom mediated by the NLPR3 or NLPR3 inflammasome pathway. Another outcome of treatment may be managing a disease, disorder, or symptom mediated by the NLPR3 or NLPR3 inflammasome pathway. Another outcome of treatment may be preventing a disease, disorder, or symptom mediated by the NLPR3 or NLPR3 inflammasome pathway.

[0145] Preventing a disease, disorder, or condition mediated by NLPR3 or the NLPR3 inflammasome pathway refers to the administration of a compound of structural formula I to a subject at risk for the disease, disorder, or condition. One outcome of prevention may be alleviating the disease, disorder, or condition mediated by the NLPR3 or NLPR3 inflammasome pathway in a subject at risk for the disease, disorder, or condition. Another outcome of prevention may be suppressing the disease, disorder, or condition mediated by the NLPR3 or NLPR3 inflammasome pathway in a subject at risk for the disease, disorder, or condition. Another outcome of prevention may be ameliorating the disease, disorder, or condition mediated by the NLPR3 or NLPR3 inflammasome pathway in a subject at risk for the disease, disorder, or condition. Another outcome of prevention may be alleviating the disease, disorder, or condition mediated by the NLPR3 or NLPR3 inflammasome pathway in a subject at risk for the disease, disorder, or condition. Another outcome of prevention may be managing a disease, disorder, or condition mediated by NLPR3 or the NLPR3 inflammasome pathway in a subject at risk of said disease, disorder, or condition.

[0146] The terms "administration" of a compound and / or "administering" a compound should be understood to mean providing a compound of structural formula I or a prodrug of a compound of structural formula I to an individual or mammal in need of treatment.

[0147] Administration of a compound of structural formula I to practice the present therapeutic method is carried out by administering an effective amount of a compound of structural formula I to a mammal in need of such treatment or prevention. The need for prophylactic administration according to the methods of the present disclosure is determined using well-known risk factors. The effective amount of a particular compound will, in the final analysis, be determined by the physician or veterinarian attending to the case; however, that effective amount will depend on a variety of factors, such as the precise disease being treated, the severity of the disease and other diseases or conditions the patient may be suffering from, the selected route of administration, other drugs and treatments the patient may require concomitantly, and other factors within the physician's judgment.

[0148] The usefulness of the present compounds in these diseases or disorders may be demonstrated in animal disease models that have been reported in the literature.

[0149] Administration and Dose Range Any suitable route of administration can be used to provide a mammal, particularly a human, with an effective dosage of a compound of structural formula I. For example, oral, intravenous, infusion, subcutaneous, transdermal, intramuscular, intradermal, transmucosal, intramucosal, rectal, topical, parenteral, ocular, pulmonary, nasal, and the like can be used. Dosage forms include tablets, troches, dispersions, suspensions, solutions, capsules, creams, ointments, aerosols, and the like. Preferably, the compound of structural formula I is administered orally.

[0150] For the treatment or prevention of disorders, diseases, and / or conditions requiring inhibition of NLRP3, suitable dosage levels are generally about 0.0001 to 500 mg / kg of patient body weight per day, which can be administered in single or multiple doses. In one embodiment, suitable dosage levels can be about 0.001 to 500 mg / kg of patient body weight per day. In another embodiment, suitable dosage levels can be about 0.001 to about 250 mg / kg per day. In another embodiment, suitable dosage levels can be about 0.01 to about 250 mg / kg per day. In another embodiment, suitable dosage levels can be about 0.1 to about 100 mg / kg per day. In another embodiment, suitable dosage levels can be about 0.05 to 100 mg / kg per day. In another embodiment, suitable dosage levels can be about 0.1 to 50 mg / kg per day. In another embodiment, a suitable dosage level may be about 0.05-0.5 mg / kg per day. In another embodiment, a suitable dosage level may be about 0.5-5 mg / kg per day. In another embodiment, a suitable dosage level may be about 5-50 mg / kg per day.For oral administration, the composition is administered in an amount of preferably 0.01 to 1000 mg of the active ingredient, particularly 0.01, 0.025, 0.05, 0.075, 0.1, 0.25, 0.5, 0.75, 1.0, 2.5, 5.0, 7.5, 10.0, 15.0, 20.0, 25.0, 30.0, 40.0, 50.0, 60.0, 70.0, 75.0, 80.0, 90.0, 100.0, 110.0, 120 .0, 125.0, 130.0, 140.0, 150.0, 160.0, 170.0, 175.0, 180.0, 190.0, 200.0, 210.0, 220.0, 225.0, 230.0, 240.0, 250.0, 260.0, 270.0, 275.0, 280.0, 290.0, 300.0, 310.0, 320.0, 325.0, 330.0, 340.0, 350.0, 360.0, 370.0, 375.0, 380.0, 390. 0, 400.0, 410.0, 420.0, 425.0, 430.0, 440.0, 450.0, 460.0, 470.0, 475.0, 480.0, 490.0, 500.0, 510.0, 520.0, 525.0, 530.0, 540.0, 550.0, 560.0, 570.0, 575.0, 580.0, 590.0, 600.0, 610.0, 620.0, 625.0, 630.0, 640.0, 650.0, 660.0, 670. The compounds are provided in the form of tablets containing 0, 675.0, 680.0, 690.0, 750.0, 800.0, 810.0, 820.0, 825.0, 830.0, 840.0, 850.0, 860.0, 870.0, 875.0, 880.0, 890.0, 900.0, 910.0, 920.0, 925.0, 930.0, 940.0, 950.0, 960.0, 970.0, 975.0, 980.0, 990.0, and 1000.0 mg of active ingredient. The compounds may be administered on a regimen of 1 to 8 times per day (preferably 1 to 4 times per day, more preferably once or twice per day, and even more preferably once per day). This dosage regimen may be adjusted to provide the optimum therapeutic response.

[0151] It will be understood, however, that the specific dosage level and frequency of administration for any particular patient may vary and will depend upon a variety of factors, including the activity of the particular compound used, the metabolic stability and length of action of that compound, age, body weight, general health, sex, diet, method and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the recipient being treated.

[0152] The compound of structural formula I can be used in a pharmaceutical composition comprising (a) the compound or a pharmaceutically acceptable salt thereof, and (b) a pharmaceutically acceptable carrier. The compound of structural formula I can be used in a pharmaceutical composition in which the compound of structural formula I or a pharmaceutically acceptable salt thereof is the only active ingredient. The compound of structural formula I can also be used in a pharmaceutical composition that includes one or more other active pharmaceutical ingredients.

[0153] The term "composition," as in pharmaceutical composition, is intended to encompass a product containing active ingredient(s) and inactive ingredient(s) that comprise the active ingredient(s), and also any product that results, directly or indirectly, from the combination, complexation, or aggregation of any two or more ingredients, or from the dissociation of one or more ingredients, or from another type of reaction or interaction of one or more ingredients. Thus, pharmaceutical compositions of the present disclosure encompass any composition made by admixing a compound of structural formula I, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, with a pharmaceutically acceptable carrier.

[0154] The compounds of structural formula I can be used in combination with other drugs that may also be useful in the treatment or amelioration of diseases or conditions for which compounds of structural formula I are useful. Such other drugs can be administered simultaneously or sequentially with the compounds of structural formula I, by a route and in an amount commonly used therefor. In treating patients suffering from chronic inflammatory conditions, two or more drugs may be administered. The compounds of structural formula I can generally be administered to patients who are already taking one or more other drugs for these conditions. Often, the compounds are administered to patients who are already being treated with one or more anti-pain compounds when the patient's pain has not adequately responded to treatment.

[0155] Combination therapy also includes therapy in which the compound of Structural Formula I and one or more other active agents are administered on different overlapping schedules. It is also contemplated that when used in combination with one or more other active ingredients, the compound of Structural Formula I and the other active agents may be used in lower doses than when each is used alone. Accordingly, pharmaceutical compositions of the present disclosure include pharmaceutical compositions that contain one or more other active agents in addition to the compound of Structural Formula I.

[0156] Examples of other active ingredients that can be administered in combination with compounds of structural formula I, which can be administered separately or in the same pharmaceutical composition, include, but are not limited to, the following: (i) anti-steatotic agents; (ii) anti-inflammatory drugs; (iii) immunology agents; (iv) lipid-lowering drugs; (v) cholesterol-lowering drugs; (vi) glucose-lowering drugs (including SGLT2 inhibitors); (vii) antiangiogenic drugs; (viii) nonsteroidal anti-inflammatory drugs (“NSAIDs”); (ix) acetylsalicylic acid drugs (ASA) (including aspirin and paracetamol); (x) regenerative therapy treatment; (xi) checkpoint inhibitors (including anti-PD1 inhibitors and anti-PDL1 inhibitors); (xii) chemotherapy; (xiii) radiation therapy; (xiv) surgical procedures; (xv) uric acid-lowering therapy; (xvi) anabolic and cartilage regeneration therapies; (xvii) antifibrotic drugs; (xviii) JAK inhibitors; (xix) TNF-α inhibitors; (xx) antihypertensive drugs; and (xxi) STING / cGAS antagonist and pharmaceutically acceptable salts of the above.

[0157] In another embodiment, the pharmaceutical composition comprises: (1) The compound of claim 1 or a pharmaceutically acceptable salt thereof; (2) One or more compounds selected from the following group or pharmaceutically acceptable salts thereof: (i) anti-steatotic agents; (ii) anti-inflammatory drugs; (iii) immunology agents; (iv) lipid-lowering drugs; (v) cholesterol-lowering drugs; (vi) glucose-lowering drugs (including SGLT2 inhibitors); (vii) antiangiogenic drugs; (viii) nonsteroidal anti-inflammatory drugs (“NSAIDs”); (ix) acetylsalicylic acid drugs (ASA) (including aspirin and paracetamol); (x) regenerative therapy treatment; (xi) checkpoint inhibitors (including anti-PD1 inhibitors and anti-PDL1 inhibitors); (xii) chemotherapy; (xiii) radiation therapy; (xiv) surgical procedures; (xv) uric acid-lowering therapy; (xvi) anabolic and cartilage regeneration therapies; (xvii) antifibrotic drugs; (xviii) JAK inhibitors; (xix) TNF-α inhibitors; (xx) antihypertensive drugs; and (xxi) a STING / cGAS antagonist; and a pharmaceutically acceptable salt thereof; and (3) A pharmaceutically acceptable carrier.

[0158] Specific compounds of use in combination with compounds of structural formula I include anti-steatotic agents, such as, but not limited to, DGAT2 inhibitors.

[0159] Suitable anti-inflammatory agents include, but are not limited to, TNFα inhibitors, JAK inhibitors, and NSAIDs.

[0160] Suitable lipid-lowering drugs include, but are not limited to, statins and PCSK9.

[0161] Suitable cancer immunology agents include, but are not limited to, PD-L1 inhibitors, PD-1 inhibitors, and STING antagonists.

[0162] Suitable glucose-lowering drugs include, but are not limited to, insulin, SGLT2 inhibitors, metformin, GLP1 antagonists, and the like.

[0163] Suitable anti-angiogenic agents include, but are not limited to, anti-VEG-F therapies.

[0164] Suitable NSAIDs or nonsteroidal anti-inflammatory drugs include, but are not limited to, aspirin, diclofenac, diflunisal, etodolac, fenoprofin, flurbiprofen, ibuprofen, indomethacin, ketoprofen, meclofenamic acid, mefenamic acid, meloxicam, naproxen, naproxen sodium, oxaprozin, piroxicam, sulindac, and tolmetin.

[0165] Suitable analgesics include, but are not limited to, acetaminophen and duloxetine.

[0166] The above combinations include not only combinations of a compound of Formula I with one other active compound, but also combinations of two or more other active compounds, including, but not limited to, combinations of a compound of Formula I with two or more active compounds selected from the following: anti-steatotic agents, anti-inflammatory agents, lipid-lowering agents, anti-fibrotic agents, immunological agents, glucose-lowering agents, anti-angiogenic agents, NSAIDs (nonsteroidal anti-inflammatory drugs), and analgesics.

[0167] The present disclosure further provides a method for treating or preventing an NLRP3-mediated disease, disorder, or condition, comprising administering to a patient in need of such treatment or at risk of developing an NLRP3-mediated disease a therapeutically effective amount of an NLRP3 inhibitor and a specific amount of one or more active ingredients, which together provide effective relief.

[0168] In a further aspect of the present disclosure, there is provided a pharmaceutical composition comprising an NLRP3 inhibitor and one or more active ingredients, together with at least one pharmaceutically acceptable carrier or excipient.

[0169]

[0013] Thus, according to a further aspect of the present disclosure, there is provided use of an NLRP3 inhibitor and one or more active ingredients for the manufacture of a medicament for treating or preventing a disease, disorder, or condition mediated by NLRP3.

[0014] Thus, in a further or alternative aspect of the present disclosure, there is provided a product comprising an NLRP3 inhibitor and one or more active ingredients as a combined preparation for simultaneous, separate, or sequential use in the treatment or prevention of a disease, disorder, or condition mediated by NLRP3.

[0015] Such a combined preparation may, for example, be in the form of a twin pack.

[0170] It is understood that for the treatment or prevention of cardiometabolic diseases, neurodegenerative diseases and inflammatory joint diseases, fibrosis, and cancer, the compounds of structural formula I may be used in combination with another pharmaceutical agent effective in treating such disease, disorder, or condition.

[0171] The present disclosure further provides a method of treating or preventing a chronic inflammatory condition, comprising administering to a patient in need of such treatment a specified amount of a compound of structural formula I and a specified amount of another agent effective to threaten the disorder, disease, or condition, whereby they together provide effective relief.

[0172] The present disclosure further provides a method of treating or preventing a chronic inflammatory condition, comprising administering to a patient in need of such treatment a specified amount of a compound of structural formula I and a specified amount of another agent useful in treating that particular condition, disorder, or disease, which together provide effective relief.

[0173] The term "therapeutically effective amount" refers to that amount of a compound of structural formula I that elicits the biological or medical response in a cell, tissue, system, animal, or human that is desired by a researcher, veterinarian, physician, or another clinician, including alleviation of symptoms of the disorder being treated. The novel methods of treatment disclosed herein are for disorders known to those skilled in the art. The term "mammal" includes humans and companion animals (e.g., dogs and cats).

[0174] The weight ratio of the compound of structural formula I to the second active ingredient can vary and depends on the effective dose of each ingredient. Generally, an effective dose of each is used. Thus, for example, when a compound of structural formula I is combined with an anti-steatotic agent, the weight ratio of the compound of structural formula I will generally be within the range of about 1000:1 to about 1:1000, preferably about 200:1 to about 1:200. Combinations of a compound of structural formula I with another active ingredient will also generally be within the aforementioned ranges, but in each case, an effective dose of each active ingredient should be used.

[0175] Synthesis method The following reaction schemes and examples illustrate methods that may be used to synthesize compounds of structural formula I described in this disclosure. These reaction schemes and examples are provided to illustrate the present disclosure and should not be construed as limiting the disclosure in any manner. All substituents are as defined above unless otherwise indicated. Several strategies based on synthetic transformations known in the organic synthesis literature can be used to prepare compounds of structural formula I. The scope of this disclosure is defined by the appended claims. Compound names were generated in Chemdraw Version 21.0.0.28.

[0176] device Reverse-phase chromatography was performed on a Waters 150 equipped with a selection of columns: Phenomenex Synergi C18 (250 mm × 30 mm × 4 microns), Phenomenex Luna C18 (250 mm × 21 mm × 5 microns), Agilent Zorbax Bonus-RP (150 mm × 21 mm × 5 microns), and Waters X-Select CSH C18 (150 mm × 19 mm × 5 microns). Conditions included either high pH (0-100% acetonitrile / water eluent with 0.1% v / v NH4OH) or low pH (0-100% acetonitrile / water eluent with 0.1% v / v TFA or formic acid), as noted in some examples. SFC chiral separations were performed on a Waters Thar 80 SFC or Berger MG II preparative SFC system.

[0177] LC / MS measurements were performed using a Waters ACQUITY UPLC equipped with a DAD and QDa MS detector under the following conditions: a Waters ACQUITY UPLC BEH C18 (1.7 mm 2.1 × 50 mm) column with a mobile phase containing A (0.1% TFA in water) and B (0.1% TFA in acetonitrile) (flow rate 0.5 mL / min, gradient 10% B → 90% B in 2 min, hold at 90% B for 0.4 min). Proton NMR or 1 H NMR was obtained using a Bruker 500 MHz NEO NMR spectrometer equipped with a 5 mm iProbe according to standard analytical techniques unless otherwise specified. Spectroscopic results are reported. Chemical shift (δ) values ​​are reported in delta (δ) units, parts per million (ppm). 1Chemical shifts for H NMR spectra are given relative to the signals of residual non-deuterated solvent (CDCl (referenced at δ 7.26 ppm), DMSO d-6 (referenced at δ 2.50 ppm), and CD3OD (referenced at δ 3.31 ppm)). Multiplets are reported with the following abbreviations: s = singlet, d = doublet, t = triplet, q = quartet, dd = doublet of doublets, dt = doublet of triplets, m = multiplet or overlap of unequal resonances. Coupling constants (J) are reported in Hertz (Hz).

[0178] Chiral Separation Methods: General preparative conditions for separating diastereomeric or enantiomeric mixtures of compounds using chiral SFC are as follows: [Table 1]

[0179] Abbreviation " in the molecule * " indicates a stereogenic center; Ac is acetyl; Ad 2n-BuPd G2 is chloro[(di(1-adamantyl)-N-butylphosphine)-2-(2-aminobiphenyl)]-palladium(II); OAc is acetate; AcOH is acetic acid; aq. is aqueous; B2pin2 is bis(pinacolato)diboron; BPin ester is boronic acid pinacol ester; Boc or boc is tert-butoxycarbonyl; br is broad line; °C is Celsius; calc'd is calculated; cat. is catalyst; δ is chemical shift; d is doublet; D is deuterium; DCM is dichloromethane; dd is doublet of doublets; DIPEA is N,N-diisopropylethylamine; DMA is dimethylacetamide; DMF is dimethylformamide; DMSO is dimethylsulfoxide; DMSO-d6 is deuterated dimethyl sulfoxide; dppf is 1,1'-bis(diphenylphosphino)-ferrocene; dtbpf is bis(di-tert-butylphosphino)ferrocene; ESI is electrospray ionization; Et is ethyl; Et3N is triethylamine; EtOAc is ethyl acetate; EtOH is ethanol; FA is formic acid; g is grams; h is hours; HPLC is high performance liquid chromatography; Hz is hertz; iPr is isopropyl; J is a coupling constant; L is liter; LC is liquid chromatography; LCMS is liquid chromatography / mass spectrometry; m is multiplet; M is mole; Me is methyl; MeCN is acetonitrile; MeOD-d4 is deuterated methanol; MeOH is methanol; mg is milligram; MHz is megahertz; min is minute; mL is milliliter; mM is millimole; mmol is millimole; μL is microliter; MPLC is medium pressure liquid chromatography; MS is mass spectrometry; n-BuOH is n-butanol; nM is nanomole; NMP is N-methylpyrrolidone; NMR is nuclear magnetic resonance; PdCl2(dppf) or Pd(dppf)Cl2 is [1,1'-bis-(diphenylphosphino)-ferrocene]dichloropalladium(II); PG is a protecting group; Ph is phenyl; POCl3 is phosphorus oxychloride; q is a quartet; qd is a quartet of doublets; rac is a racemic mixture; s is a singlet; sat. is saturated; SFC is supercritical fluid chromatography; S N Ar is nucleophilic aromatic substitution; t is triplet; t-AmOH is tert-amyl alcohol; t-Bu or t Bu is tert-butyl; tert is tertiary; TFA is trifluoroacetic acid; THF is tetrahydrofuran; TLC is thin layer chromatography; tt is triplet of triplets; XPhos Pd G3 is (2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) methanesulfonate; UV is ultraviolet; and wt% is weight percent.

[0180] General scheme Scheme A [ka]

[0181] Scheme A shows a synthetic sequence for preparing biarylpyridazine derivatives of formula A-4. Dihaloaminopyridazine A-1 is converted to various primary amines in a regioselective S-directed manner. N Ar affords diamines such as A-2. Cyclization of diamine A-2 with an appropriate orthoester affords imidazopyridazines of formula A-3. Palladium-catalyzed cross-coupling with an appropriate aryl nucleophile (e.g., arylboronic acid) affords biaryl products, which, if applicable, can be deprotected in situ to afford compounds of formula A-4.

[0182] Scheme B [ka]

[0183] Scheme B shows a synthetic sequence for preparing biarylpyridazine derivatives of formula B-7. Methyltrihalopyridazine B-1 is regioselectively reacted with sodium benzenesulfinate to generate sulfone B-2, which is then reacted with sodium benzenesulfinate to form sulfone B-3. N Coupling with various primary amines under Ar conditions can form aminopyrididines such as B-3. Displacement of the sulfone with sodium azide generates aminoazidopyridazine B-4, which can be treated with Zn in AcOH and then reduced to diaminopyrazine B-5. Cyclization of diamine B-5 with an appropriate orthoester provides imidazopyridazines of formula B-6. Palladium-catalyzed cross-coupling with an appropriate aryl nucleophile (e.g., arylboronic acid) affords the biaryl product, which can be deprotected in situ (if applicable) to give compounds of formula B-7.

[0184] Scheme C [ka]

[0185] Scheme C shows a synthetic sequence for preparing biaryl pyrrolopyridazine derivatives of formula C-5. Trihalopyridazine C-1 undergoes monoselective cross-coupling with an appropriate vinylboron reagent to give vinyl derivatives such as C-2. Reaction of vinyl derivative C-2 with various primary amines in the presence of a base (e.g., DIPEA) generates dihydropyrrolopyridazines of formula C-3. Oxidation with manganese oxide at elevated temperature in a suitable solvent (e.g., toluene) affords the pyrrolopyridazine core of formula C-4. Palladium-catalyzed cross-coupling with an appropriate aryl nucleophile (e.g., arylboronic acid) affords the biaryl product, which, if applicable, can be deprotected in situ to give compounds of formula C-5.

[0186] Scheme D [ka]

[0187] Scheme D shows a synthetic sequence for preparing biarylpyrrolopyridazine derivatives of formula D-5. Various primary amines are alkylated with bromopentine D-1 to generate aminoalkynes of formula D-2. The aminoalkynes D-2 are reacted with dichlorotetrazine in the presence of a base (e.g., EtN) at elevated temperature to afford the S NAr, hetero Diels-Alder cycloaddition, and retro Diels-Alder sequence directly afford pyridazopyrrolidines of formula D-3. Oxidation using manganese oxide at elevated temperature in a suitable solvent (e.g., toluene) affords the pyrrolopyridazine core of formula D-4. Palladium-catalyzed cross-coupling with an appropriate aryl nucleophile (e.g., arylboronic acid) affords the biaryl product, which, if applicable, can be deprotected in situ to afford compounds of formula D-5.

[0188] Scheme E [ka]

[0189] Scheme E shows a synthetic sequence for preparing biarylpyridazine derivatives of formula E-3. N-Boc cyclic amine E-1 can be deprotected with an acid (e.g., TFA or HCl) to give secondary amines such as E-2. E-2 undergoes reductive amination with an appropriate aldehyde or ketone in the presence of a reducing agent (e.g., sodium cyanoborohydride or sodium triacetoxyborohydride) to give trialkylamines of formula E-3. [Example]

[0190] Intermediate 1 (R)-6-chloro-N 3 -(1-ethylpiperidin-3-yl)pyridazine-3,4-diamine [ka] A suspension of 3,6-dichloropyridazin-4-amine (Ambeed, 800 mg, 4.88 mmol) and (R)-1-ethylpiperidin-3-amine (Enamine, 688 mg, 5.37 mmol) in n-BuOH (1.63 mL) was treated with DIPEA (1.19 mL, 6.83 mmol). The reaction mixture was heated to 150° C. for 2 days. The reaction mixture was then cooled to room temperature, filtered, and purified by preparative reverse-phase HPLC (C18 stationary phase, MeCN / water with 0.1% TFA) to provide the title compound.

[0191] LCMS [M+H] + = 256.2 (calculated value 256.2)

[0192] Table 1. The following intermediates were prepared using procedures similar to those described for Intermediate 1 using the appropriate starting materials. [Table 2]

[0193] Intermediate 3 (R)-6-chloro-N 3 -(1-ethylpiperidin-3-yl)-5-methylpyridazine-3,4-diamine [ka] Step 1: 3,4,6-trichloro-5-methylpyridazine: A solution of 4-bromo-5-methylpyridazine-3,6-diol (Enamine, 1.20 g, 5.85 mmol) and POCl (10 mL, 107 mmol) was stirred at 100 °C for 2 h. The mixture was then cooled to room temperature and slowly added to water. The mixture was diluted with EtOAc, the layers were separated, and the aqueous layer was extracted with EtOAc (×2). The combined organic layers were concentrated, and the crude residue was purified by silica gel chromatography (EtOAc:petroleum ether) to provide the title compound.

[0194] LCMS [M+H] + = 197.1 (calculated value 196.9)

[0195] Step 2: Phenyl 3,6-dichloro-5-methylpyridazine-4-sulfinate: A solution of 3,4,6-trichloro-5-methylpyridazine (6.4 g, 32.4 mmol) in THF (50 mL) and DMSO (10 mL) was treated with sodium benzenesulfinate (5.6 g, 34.0 mmol). The resulting reaction mixture was heated to 40° C. for 48 h. The reaction mixture was then cooled to room temperature and diluted with water and EtOAc. The layers were separated, and the aqueous layer was extracted with EtOAc (×3). The combined organic layers were concentrated, and the crude residue was purified by silica gel chromatography (EtOAc:petroleum ether) to provide the title compound.

[0196] LCMS [M+H] + = 303.1 (calculated value 303.0)

[0197] Step 3: 6-chloro-3-(((R)-1-ethylpiperidin-3-yl)amino)-5-methylpyridazin-4-ylbenzenesulfinate: A solution of phenyl 3,6-dichloro-5-methylpyridazine-4-sulfinate (1.5 g, 4.95 mmol) in 1,4-dioxane (30 mL) was treated with (R)-1-ethylpiperidin-3-amine (Enamine, 952 mg, 7.42 mmol) and KCO (3.08 g, 22.3 mmol). The resulting mixture was heated to 100 °C for 12 h. After cooling to room temperature, the reaction mixture was filtered and purified by preparative reverse-phase HPLC (C18 stationary phase, MeCN / water with 0.05% TFA) to provide the title compound.

[0198] LCMS [M+H] + = 395.1 (calculated value 395.1)

[0199] Step 4: (R)-4-azido-6-chloro-N-(1-ethylpiperidin-3-yl)-5-methylpyridazin-3-amine:A solution of 6-chloro-3-(((R)-1-ethylpiperidin-3-yl)amino)-5-methylpyridazin-4-ylbenzenesulfinate (500 mg, 1.27 mmol) in 1,4-dioxane (8 mL) and DMSO (2 mL) was treated with NaN (494 mg, 7.60 mmol). The resulting mixture was heated to 50 °C for 12 h. After cooling to room temperature, the reaction mixture was filtered and purified by preparative reverse-phase HPLC (C stationary phase, MeCN / water + 0.05% NHOH + 10 mM NHHCO) to provide the title compound.

[0200] LCMS [M+H] + = 296.2 (calculated value 296.1).

[0201] Step 5: (R)-6-chloro-N 3 -(1-ethylpiperidin-3-yl)-5-methylpyridazine-3,4-diamine: A solution of (R)-4-azido-6-chloro-N-(1-ethylpiperidin-3-yl)-5-methylpyridazin-3-amine (300 mg, 1.01 mmol) in DCM (5 mL) and AcOH (1 mL) was cooled to 0° C. and treated with zinc (133 mg, 2.03 mmol). The resulting mixture was stirred at 0° C. for 2 h, then filtered and concentrated to provide the title compound.

[0202] LCMS [M+H] + = 270.1 (calculated value 270.1)

[0203] Table 2. The following intermediates were prepared using procedures similar to that described for Intermediate 3, using the appropriate commercially available amines. A modified procedure was used in Step 4, using pure DMSO as the solvent and a reaction temperature of 60° C. The compounds were purified in all component steps using silica gel chromatography instead of reverse-phase HPLC. [Table 3]

[0204] Intermediate 6 (R)-3-chloro-7-(1-ethylpiperidin-3-yl)-7H-imidazo[4,5-c]pyridazine [ka] (R)-6-chloro-N in trimethyl orthoformate (4.2 mL) 3 A suspension of -(1-ethylpiperidin-3-yl)pyridazine-3,4-diamine (Intermediate 1, 400 mg, 1.56 mmol) was treated with HCl (4 M in 1,4-dioxane, 380 μL, 1.52 mmol). The reaction mixture was heated to 100° C. for 2 hours. The reaction mixture was then cooled to room temperature and concentrated. The crude residue obtained was purified by silica gel chromatography (MeOH:DCM) to provide the title compound.

[0205] LCMS [M+H] + = 266.2 (calculated value 266.1).

[0206] Table 3. The following intermediates were prepared using procedures similar to those described for Intermediate 6 using the appropriate starting materials. [Table 4]

[0207] Intermediate 11 tert-Butyl (R)-3-(3-chloro-7H-pyrrolo[2,3-c]pyridazin-7-yl)piperidine-1-carboxylate [ka] Step 1: 3,6-dichloro-4-vinylpyridazine:A suspension of 4-bromo-3,6-dichloropyridazine (Combi-Blocks, 3.00 g, 13.2 mmol), potassium vinyltrifluoroborate (1.85 g, 13.8 mmol), and CsCO (12.9 g, 39.5 mmol) in 1,4-dioxane (44 mL) and water (9 mL) was degassed with argon for 10 min. Pd(dppf)Cl (482 mg, 0.658 mmol) was then added, and the mixture was heated to 50 °C with stirring under argon for 1.5 h. The reaction mixture was then cooled to room temperature and diluted with H2O and DCM. The layers were separated, and the organic phase was dried over Na2SO4, filtered, and the solvent removed. The resulting crude residue containing the title compound was used in the next step without further purification.

[0208] Step 2: tert-butyl (R)-3-(3-chloro-5,6-dihydro-7H-pyrrolo[2,3-c]pyridazin-7-yl)piperidine-1-carboxylate: A sealed vial was charged with 3,6-dichloro-4-vinylpyridazine (100 mg, 0.571 mmol) and 1,4-dioxane (2.5 mL). DIPEA (200 μL, 1.14 mmol) and tert-butyl (R)-3-aminopiperidine-1-carboxylate (Pharmablock, 122 μL, 0.686 mmol) were then added. The vial was sealed, and the reaction mixture was heated to 150° C. for 2 hours. The reaction mixture was then cooled to room temperature and concentrated. The crude residue was purified by silica gel chromatography (EtOAc:hexanes) to provide the title compound. LCMS [M+H] + = 339.3 (calculated value 339.2).

[0209] Step 3: tert-butyl (R)-3-(3-chloro-7H-pyrrolo[2,3-c]pyridazin-7-yl)piperidine-1-carboxylate:A solution of tert-butyl (R)-3-(3-chloro-5,6-dihydro-7H-pyrrolo[2,3-c]pyridazin-7-yl)piperidine-1-carboxylate (135 mg, 0.398 mmol) in toluene (8 mL) was treated with MnO (225 mg, 2.59 mmol). The reaction mixture was heated to 125 °C for 2.5 days. The reaction mixture was then cooled to room temperature, filtered through Celite®, and concentrated. The crude residue was purified by silica gel chromatography (EtOAc:hexanes) to provide the title compound.

[0210] LCMS [M+Na] + = 359.2 (calculated value 359.1).

[0211] Intermediate 12 tert-Butyl (R)-3-(3-chloro-4-methyl-7H-pyrrolo[2,3-c]pyridazin-7-yl)piperidine-1-carboxylate [ka] Step 1: tert-butyl (R)-3-(pent-3-yn-1-ylamino)piperidine-1-carboxylate: A suspension of tert-butyl (R)-3-aminopiperidine-1-carboxylate (Pharmablock, 1.50 g, 7.48 mmol) and KCO (1.41 g, 10.2 mmol) in MeCN (27 mL) was treated with 5-bromopent-2-yne (Enamine, 1.00 g, 6.80 mmol). The mixture was heated to 80 °C with stirring for 12 h. The reaction mixture was then cooled to room temperature, filtered, and concentrated. The crude residue was purified by silica gel chromatography (EtOAc:hexanes) to provide the title compound. LCMS [M+H] + = 267.2 (calculated value 267.2).

[0212] Step 2: tert-butyl (R)-3-(3-chloro-4-methyl-5,6-dihydro-7H-pyrrolo[2,3-c]pyridazin-7-yl)piperidine-1-carboxylate:A solution of 3,6-dichloro-1,2,4,5-tetrazine (Pharmablock, 75 mg, 0.500 mmol) in THF (2 mL) in a sealed tube was treated with EtN (77 μL, 0.550 mmol) and tert-butyl (R)-3-(pent-3-yn-1-ylamino)piperidine-1-carboxylate (133 mg, 0.5 mmol). The reaction mixture was heated to 110° C. for 16 h. The reaction mixture was then cooled to room temperature and diluted with water and EtOAc. The mixture was filtered through Celite®. The layers were separated, and the aqueous layer was extracted with EtOAc (×3). The combined organic layers were dried over anhydrous MgSO, filtered, and concentrated. The crude residue was purified by silica gel chromatography (EtOAc:hexanes) to provide the title compound.

[0213] LCMS [M+H] + = 353.2 (calculated value 353.2).

[0214] Step 3: tert-butyl (R)-3-(3-chloro-4-methyl-7H-pyrrolo[2,3-c]pyridazin-7-yl)piperidine-1-carboxylate: A solution of tert-butyl (R)-3-(3-chloro-4-methyl-5,6-dihydro-7H-pyrrolo[2,3-c]pyridazin-7-yl)piperidine-1-carboxylate (70 mg, 0.20 mmol) in toluene (4 mL) was treated with MnO (103 mg, 1.19 mmol). The reaction mixture was heated to 125 °C for 2.5 days. The reaction mixture was then cooled to room temperature, filtered through Celite®, and concentrated. The crude residue was purified by silica gel chromatography (EtOAc:hexanes) to provide the title compound.

[0215] LCMS [M+Na] + = 373.3 (calculated value 373.1)

[0216] Intermediate 13 2-(2-(ethoxymethoxy)-6-methyl-4-(trifluoromethyl)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane [ka] Step 1: 3-methyl-5-(trifluoromethyl)phenol:To a solution of 3-bromo-5-(trifluoromethyl)phenol (Carbosynth, 500 g, 2.07 mol), K2CO3 (859 g, 6.22 mol), and Pd(dppf)Cl2 (75.8 g, 103.7 mmol) in 1,4-dioxane (7.5 L) under a N2 atmosphere, trimethyl-1,3,5,2,4,6-trioxatriborinane (Aldrich, 1.04 kg, 4.15 mol, 50 wt% in THF) was added portionwise. The resulting mixture was stirred at 100 °C for 12 h and then cooled to 25 °C. The reaction was quenched with ice water at 0 °C and diluted with EtOAc. The organic layer was separated, washed with brine, dried over anhydrous Na2SO4, and concentrated. The crude residue was purified by silica gel chromatography (EtOAc:petroleum ether) to give the title compound.

[0217] LCMS [MH] - = 175.1 (calculated value 175.0).

[0218] Step 2: 2-iodo-3-methyl-5-(trifluoromethyl)phenol: To a stirred solution of 3-methyl-5-(trifluoromethyl)phenol (283 g, 1.61 mol) in toluene (1.42 L) was added NaH (128.5 g, 3.21 mol, 60 wt%) at 0 °C under a N atmosphere. The resulting mixture was stirred at 0 °C for 30 min, followed by the portionwise addition of I (306.1 g, 1.21 mmol) in toluene (5.66 L). The reaction was stirred at 20 °C for 3 h and then quenched by pouring into a water / ice bath. The mixture was diluted with EtOAc, and the layers were separated. The organic layer was washed with brine, dried over anhydrous NaSO, and the solvent was removed under reduced pressure. The resulting crude residue containing the title compound was used in the next step without further purification.

[0219] Step 3: 1-(ethoxymethoxy)-2-iodo-3-methyl-5-(trifluoromethyl)benzene:To a stirred solution of 2-iodo-3-methyl-5-(trifluoromethyl)phenol (463 g, 1.53 mol) and CsCO (999 g, 3.07 mmol) in DMF (4.6 L) under a N atmosphere was added chloromethyl ethyl ether (290 g, 3.07 mol) at 0 °C. The resulting mixture was stirred at room temperature for 8 h, then cooled to 0 °C and quenched by the addition of ice water. The resulting mixture was diluted with EtOAc, and the organic layer was separated, washed with brine, and dried over anhydrous NaSO. The solvent was removed under reduced pressure, and the crude residue was purified by silica gel chromatography (EtOAc:petroleum ether) to give the title compound.

[0220] 1 H NMR (300 MHz, DMSO-d6) δ 7.55 (s, 1H), 7.18 (s, 1H), 5.42 (s, 2H), 3.75 - 3.65 (m, 2H), 2.50 (s, 3H), 1.21 - 1.10 (m, 3H).

[0221] Step 4: 2-(2-(ethoxymethoxy)-6-methyl-4-(trifluoromethyl)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane: A mixture of 1-(ethoxymethoxy)-2-iodo-3-methyl-5-(trifluoromethyl)benzene (330 g, 916.4 mmol), B2pin2 (469 g, 3.67 mol), Et3N (556 g, 5.50 mol), Pd(OAc)2 (10.3 g, 45.8 mmol), and biphenyl-2-yl-dicyclohexylphosphine (32.1 g, 91.6 mmol) in 1,4-dioxane (3.3 L) was placed under a N2 atmosphere. The resulting solution was stirred at 100 °C for 6 h, cooled to 25 °C, and quenched with ice-water. The mixture was filtered, and the solid residue was washed with EtOAc. The organic filtrate layer was separated, washed with brine, dried over anhydrous Na2SO4, and concentrated. The crude residue was purified by silica gel chromatography (EtOAc:petroleum ether), and the desired fractions were concentrated. The resulting solid was dissolved in hexane and stirred for 5 minutes at −30° C. The precipitated solid was collected by filtration to give the title compound.

[0222] 1H NMR (300 MHz, CDCl3) δ 7.13-7.03 (m, 2H), 5.23 (s, 2H), 3.74 (q, J = 7.1 Hz, 2H), 2.41 (s, 3H), 1.41 (s, 12H), 1.24 (t, J = 7.1 Hz, 3H).

[0223] Intermediate 14 2-(2-(difluoromethoxy)-4-(trifluoromethyl)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane [ka] A solution of 1-bromo-2-(difluoromethoxy)-4-(trifluoromethyl)benzene (enamine, 200 mg, 0.687 mmol) in toluene (5 mL) was treated with B2pin2 (0.262 g, 1.031 mmol), KOAc (0.202 g, 2.062 mmol), and PdCl2(dppf) (Aldrich, 0.050 g, 0.069 mmol). After cooling to room temperature, the reaction mixture was concentrated, and the crude residue was purified by silica gel chromatography (EtOAc:petroleum ether) to give the title compound.

[0224] 1 H NMR (CDCl3, 400 MHz) δ 7.88 (d, J = 7.6 Hz, 1H), 7.51 (d, J = 7.7 Hz, 1H), 7.41 (s, 1H), 6.56 (t, J = 58.0 Hz, 1H), 1.37 (s, 12H).

[0225] Example 1 (R)-2-(7-(1-ethylpiperidin-3-yl)-7H-pyrrolo[2,3-c]pyridazin-3-yl)-3-methyl-5-(trifluoromethyl)phenol [ka] Step 1: tert-butyl (R)-3-(3-(2-(ethoxymethoxy)-6-methyl-4-(trifluoromethyl)phenyl)-7H-pyrrolo[2,3-c]pyridazin-7-yl)piperidine-1-carboxylate:A first vial was charged with tert-butyl (R)-3-(3-chloro-7H-pyrrolo[2,3-c]pyridazin-7-yl)piperidine-1-carboxylate (Intermediate 11, 78 mg, 0.232 mmol), 2-(2-(ethoxymethoxy)-6-methyl-4-(trifluoromethyl)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (Intermediate 13, 125 mg, 0.347 mmol), XPhos Pd G3 (16.6 mg, 0.019 mmol), and potassium carbonate (160 mg, 1.16 mmol), then evacuated and backfilled with N. In a second vial, a solvent mixture of 1,4-dioxane (1.2 mL) and water (0.3 mL) was sparged with N for 15 minutes and then added to the first vial. The reaction mixture was heated to 100° C. for 3 h, then cooled to room temperature and diluted with water and DCM. The layers were separated and the aqueous layer was extracted with DCM (×3). The combined organic layers were dried over anhydrous MgSO4, filtered, and concentrated. The crude residue was purified by silica gel chromatography (EtOAc:hexanes) to provide the title compound.

[0226] [M+H] + = 535.2 (calculated value 535.3).

[0227] Step 2: (R)-3-methyl-2-(7-(piperidin-3-yl)-7H-pyrrolo[2,3-c]pyridazin-3-yl)-5-(trifluoromethyl)phenol hydrochloride: A solution of tert-butyl (R)-3-(3-(2-(ethoxymethoxy)-6-methyl-4-(trifluoromethyl)phenyl)-7H-pyrrolo[2,3-c]pyridazin-7-yl)piperidine-1-carboxylate (121 mg, 0.226 mmol) in 1,4-dioxane (2.3 mL) was treated with HCl (4 M in 1,4-dioxane, 283 μL, 1.13 mmol). The reaction mixture was heated to 70° C. and stirred for 3 hours. The reaction mixture was then cooled to room temperature, and the precipitated solid was collected by filtration to provide the title compound.

[0228] LCMS [M+H] + = 377.2, (calculated value 377.2).

[0229] Step 3: (R)-2-(7-(1-ethylpiperidin-3-yl)-7H-pyrrolo[2,3-c]pyridazin-3-yl)-3-methyl-5-(trifluoromethyl)phenol:A solution of (R)-3-methyl-2-(7-(piperidin-3-yl)-7H-pyrrolo[2,3-c]pyridazin-3-yl)-5-(trifluoromethyl)phenol, hydrochloride (72 mg, 0.174 mmol) and acetaldehyde (20 μL, 0.35 mmol) in DCM (1.7 mL) was treated with sodium triacetoxyborohydride (74 mg, 0.35 mmol). The resulting reaction mixture was stirred at 25° C. for 1 h, then quenched with water and partitioned with 10% MeOH in DCM. The layers were separated, and the aqueous layer was extracted with 10% MeOH in DCM (×2). The combined organic layers were dried over anhydrous MgSO4, filtered, and concentrated. The resulting crude residue was taken up in DMSO, filtered, and purified by preparative reverse phase HPLC (C18 stationary phase, MeCN / water with 0.05% FA) to afford the title compound.

[0230] LCMS [M+H] + = 405.2, (calculated value 405.2). 1 H NMR (500 MHz, DMSO-d6) 10.02 (s, 1H), 8.15 (d, J = 3.1 Hz, 1H), 7.80 (s, 1H), 7.15 (s, 1H), 7.09 (s, 1H), 6.60 (d, J = 3.3 Hz, 1H), 5.10 (br s, 1H), 3.29 - 3.26 (m, 1H), 3.13 (br s, 1H), 2.88 (br s, 1H), 2.61 - 2.54 (m, 2H), 2.21 (s, 1H), 2.09 - 2.02 (m, 2H), 2.05 (s, 3H), 1.86 - 1.81 (m, 1H), 1.72 (br s, 1H), 1.04 (t, J = 7.1 Hz, 3H).

[0231] Table 4. The following compounds were prepared using procedures similar to those described for Example 1 using the appropriate starting materials. [Table 5]

[0232] Example 3 (R)-2-(7-(1-ethylpiperidin-3-yl)-7H-imidazo[4,5-c]pyridazin-3-yl)-3-methyl-5-(trifluoromethyl)phenol [ka] Step 1: (R)-3-(2-(ethoxymethoxy)-6-methyl-4-(trifluoromethyl)phenyl)-7-(1-ethylpiperidin-3-yl)-7H-imidazo[4,5-c]pyridazine: A vial was charged with (R)-3-chloro-7-(1-ethylpiperidin-3-yl)-7H-imidazo[4,5-c]pyridazine (Intermediate 6, 100 mg, 0.376 mmol), 2-(2-(ethoxymethoxy)-6-methyl-4-(trifluoromethyl)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (Intermediate 13, 203 mg, 0.564 mmol), XPhos Pd G3 (26 mg, 0.030 mmol), and potassium carbonate (260 mg, 1.88 mmol). The vial was then evacuated and backfilled with nitrogen (3x). In a second vial, a solvent mixture of 1,4-dioxane (2 mL) and water (0.5 mL) was sparged with nitrogen for 15 minutes and then added to the first vial. The reaction was heated to 100° C. for 3 hours. The reaction mixture was then cooled to room temperature and diluted with water and DCM. The layers were separated and the aqueous layer was extracted with DCM (×3). The combined organic layers were dried over anhydrous MgSO4, filtered, and concentrated. The crude residue was purified by silica gel chromatography (MeOH:DCM) to provide the title compound.

[0233] LCMS [M+H] + = 464.4 (calculated value 464.2).

[0234] Step 2: (R)-2-(7-(1-ethylpiperidin-3-yl)-7H-imidazo[4,5-c]pyridazin-3-yl)-3-methyl-5-(trifluoromethyl)phenol:A solution of (R)-3-(2-(ethoxymethoxy)-6-methyl-4-(trifluoromethyl)phenyl)-7-(1-ethylpiperidin-3-yl)-7H-imidazo[4,5-c]pyridazine (30 mg, 0.065 mmol) in 1,4-dioxane (0.65 mL) was treated with HCl (4 M in 1,4-dioxane, 81 μL, 0.324 mmol). The reaction mixture was heated to 70° C. and stirred for 3 h. The reaction mixture was then cooled to room temperature and concentrated. The crude residue obtained was taken up in DMSO, filtered, and purified by preparative reverse-phase HPLC (C18 stationary phase, MeCN / water with 0.05% FA) to provide the title compound.

[0235] LCMS [M+H] + = 406.4 (calculated value 406.2). 1 H NMR (500 MHz, MeOD-d4) δ 8.94 (s, 1H), 7.92 (s, 1H), 7.09 (s, 1H), 7.05 (s, 1H), 5.07 - 4.97 (m, 1H), 3.30 - 3.22 (m, 1H), 2.89 - 2.75 (m, 2H), 2.56 - 2.47 (m, 2H), 2.38 - 2.15 (m, 3H), 2.09 (s, 3H), 1.93 - 1.72 (m, 2H), 1.10 (t, J = 7.2 Hz, 3H).

[0236] Table 5. The following compounds were prepared using procedures similar to those described for Example 3 using the appropriate starting materials. [Table 6]

[0237] Example 7 (R)-2-(7-(1-ethylpiperidin-3-yl)-4-methyl-7H-imidazo[4,5-c]pyridazin-3-yl)-5-(trifluoromethyl)phenol [ka] A solution of (R)-3-chloro-7-(1-ethylpiperidin-3-yl)-4-methyl-7H-imidazo[4,5-c]pyridazine (Intermediate 8, 40 mg, 0.143 mmol) in 1,4-dioxane (3 mL) and water (0.8 mL) was treated with (2-hydroxy-4-(trifluoromethyl)phenyl)boronic acid (Combi-Blocks, 35.3 mg, 0.172 mmol), KCO (59.3 mg, 0.429 mmol), and PdCl(dppf) (10.5 mg, 0.014 mmol). The mixture was degassed with argon and then heated to 100 °C for 12 h. After cooling to room temperature, the reaction mixture was filtered and concentrated. The resulting crude residue was purified by preparative reverse phase HPLC (C18 stationary phase, MeCN / water with 0.05% TFA) to afford the title compound.

[0238] LCMS [M+H] + = 406.2, (calculated value 406.2). 1 H NMR (400 MHz, MeOD-d4) δ 8.82 (s, 1H), 7.51 (d, J = 7.9 Hz, 1H), 7.33 (d, J = 7.2 Hz, 1H), 7.27 (s, 1H), 5.17 (br s, 1H), 4.07 (br d, J = 10.8 Hz, 1H), 3.79 - 3.62 (m, 2H), 3.36 (br s, 2H), 3.14 (br t, J = 12.4 Hz, 1H), 2.61 (br s, 1H), 2.56 (s, 3H), 2.46 (br s, 1H), 2.32 (br d, J = 14.7 Hz, 1H), 2.16 - 2.00 (m, 1H), 1.41 (br t, J = 7.2 Hz, 3H).

[0239] Table 6. The following compounds were prepared using procedures similar to those described for Example 7 using the appropriate starting materials. [Table 7]

[0240] Example 10 (R)-2-(4-methyl-7-(1-methylpiperidin-3-yl)-7H-imidazo[4,5-c]pyridazin-3-yl)-5-(trifluoromethyl)phenol [ka] A mixture of (R)-2-(4-methyl-7-(piperidin-3-yl)-7H-imidazo[4,5-c]pyridazin-3-yl)-5-(trifluoromethyl)phenol (Example 5, 20 mg, 0.053 mmol) in MeOH (0.27 mL) and THF (0.27 mL) was treated with formaldehyde (37% in water, 24 μL, 0.318 mmol) and sodium triacetoxyborohydride (34 mg, 0.159 mmol). The reaction mixture was stirred at 25° C. for 1 h. The reaction was then quenched with 4 drops of AcOH and concentrated. The crude residue obtained was taken up in DMSO, filtered, and purified by preparative reverse-phase HPLC (C18 stationary phase, MeCN / water with 0.1% TFA) to provide the title compound.

[0241] LCMS [M+H] + = 392.3 (calculated value 392.2). 1 H NMR (500 MHz, MeOD-d4) δ 8.88 (s, 1H), 7.48 (d, J = 7.8 Hz, 1H), 7.29 (d, J = 8.0 Hz, 1H), 7.24 (s, 1H), 5.10 - 5.00 (m, 1H), 3.40 - 3.28 (m, 2H), 3.08 - 2.88 (m, 2H), 2.51 (s, 3H), 2.51 (s, 3H), 2.36 - 2.21 (m, 2H), 2.04 - 1.83 (m, 2H).

[0242] Example 10 (Alternative Synthesis) (R)-2-(4-methyl-7-(1-methylpiperidin-3-yl)-7H-imidazo[4,5-c]pyridazin-3-yl)-5-(trifluoromethyl)phenol [ka] Step 1: 3,4,6-trichloro-5-methylpyridazine:A solution of 4-bromo-5-methylpyridazine-3,6-diol (Enamine, 1.20 g, 5.85 mmol) and POCl (10 mL, 107 mmol) was stirred at 100 °C for 2 h. The mixture was then cooled to room temperature, and water was slowly added. The mixture was diluted with EtOAc, the layers were separated, and the aqueous layer was extracted with EtOAc (×2). The combined organic layers were concentrated, and the crude residue was purified by silica gel chromatography (EtOAc:petroleum ether) to provide the title compound.

[0243] LCMS [M+H] + = 197.1 (calculated value 196.9).

[0244] Step 2: Phenyl 3,6-dichloro-5-methylpyridazine-4-sulfinate: A solution of 3,4,6-trichloro-5-methylpyridazine (6.4 g, 32.4 mmol) in THF (50 mL) and DMSO (10 mL) was treated with sodium benzenesulfinate (5.6 g, 34.0 mmol). The resulting reaction mixture was heated to 40° C. for 48 h. The reaction mixture was then cooled to room temperature and diluted with water and EtOAc. The layers were separated, and the aqueous layer was extracted with EtOAc (×3). The combined organic layers were concentrated, and the crude residue was purified by silica gel chromatography (EtOAc:petroleum ether) to provide the title compound.

[0245] LCMS [M+H] + = 303.1 (calculated value 303.0).

[0246] Step 3: tert-butyl (R)-3-((6-chloro-5-methyl-4-(phenylsulfonyl)pyridazin-3-yl)amino)piperidine-1-carboxylate:Two 40 mL scintillation vials were set up in duplicate. In each vial, a solution of phenyl 3,6-dichloro-5-methylpyridazine-4-sulfinate (750 mg, 2.47 mmol) in 1,4-dioxane (15 mL) was treated with tert-butyl (R)-3-aminopiperidine-1-carboxylate (Aldrich, 743 mg, 3.71 mmol) and K2CO3 (1.54 g, 11.1 mmol). The resulting mixture was heated to 100 °C for 5 h. After cooling to room temperature, the reaction mixtures were combined, filtered, and concentrated under reduced pressure. The crude residue was purified by silica gel chromatography (25% EtOH in EtOAc:hexanes) to provide the title compound.

[0247] LCMS [M+Na] + = 489.4 (calculated value 489.1).

[0248] Step 4: tert-butyl (R)-3-((4-azido-6-chloro-5-methylpyridazin-3-yl)amino)piperidine-1-carboxylate: A solution of tert-butyl (R)-3-((6-chloro-5-methyl-4-(phenylsulfonyl)pyridazin-3-yl)amino)piperidine-1-carboxylate (1.50 g, 3.21 mmol) in DMSO (23 mL) was treated with NaN (1.25 g, 19.3 mmol). The resulting mixture was heated to 60 °C for 5 h. After cooling to room temperature, the reaction mixture was quenched with water and extracted with EtOAc (3x). The combined organic layers were washed with water (2x) and brine, dried over anhydrous MgSO, filtered, and concentrated under reduced pressure. The crude residue was purified by silica gel chromatography (MeOH:DCM) to provide the title compound.

[0249] LCMS [M+H] + = 368.2 (calculated value 368.2).

[0250] Step 5: tert-butyl (R)-3-((4-amino-6-chloro-5-methylpyridazin-3-yl)amino)piperidine-1-carboxylate:A solution of tert-butyl (R)-3-((4-azido-6-chloro-5-methylpyridazin-3-yl)amino)piperidine-1-carboxylate (686 mg, 1.87 mmol) in DCM (9.1 mL) and AcOH (1.8 mL) was cooled to 0° C. and treated with zinc (244 mg, 3.73 mmol). The resulting mixture was stirred at 0° C. for 2 h, then filtered and concentrated in vacuo to provide the title compound.

[0251] LCMS [M+H] + = 342.2 (calculated value 342.2).

[0252] Step 6: tert-butyl (R)-3-(3-chloro-4-methyl-7H-imidazo[4,5-c]pyridazin-7-yl)piperidine-1-carboxylate: A solution of tert-butyl (R)-3-((4-amino-6-chloro-5-methylpyridazin-3-yl)amino)piperidine-1-carboxylate (1.10 g, 3.22 mmol) in trimethyl orthoformate (21.5 mL) was treated with HCl (4 M in 1,4-dioxane, 40 μL, 0.161 mmol). The reaction mixture was heated to 100° C. for 2 hours. After cooling to room temperature, the reaction mixture was concentrated under reduced pressure. The crude residue obtained was purified by silica gel chromatography (MeOH:DCM) to provide the title compound.

[0253] LCMS [M+H] + = 352.4 (calculated value 352.2).

[0254] Step 7: tert-butyl (R)-3-(3-(2-hydroxy-4-(trifluoromethyl)phenyl)-4-methyl-7H-imidazo[4,5-c]pyridazin-7-yl)piperidine-1-carboxylate:A vial was charged with tert-butyl (R)-3-(3-chloro-4-methyl-7H-imidazo[4,5-c]pyridazin-7-yl)piperidine-1-carboxylate (700 mg, 1.99 mmol), (2-hydroxy-4-(trifluoromethyl)phenyl)boronic acid (Combi-Blocks, 615 mg, 2.98 mmol), XPhos Pd G3 (135 mg, 0.159 mmol), and potassium carbonate (1.38 g, 9.95 mmol). The vial was then evacuated and backfilled with nitrogen (3x). In a second vial, a solvent mixture of 1,4-dioxane (10.6 mL) and water (2.7 mL) was sparged with nitrogen for 15 minutes and then added to the first vial. The reaction was heated to 100°C for 3 hours. The reaction mixture was then cooled to room temperature and diluted with water and DCM. The layers were separated and the aqueous layer was extracted with DCM (x3). The combined organic layers were dried over anhydrous MgSO, filtered, and concentrated under reduced pressure. The crude residue was purified by silica gel chromatography (MeOH:DCM) to provide the title compound.

[0255] LCMS [M+H] + = 478.4 (calculated value 478.2).

[0256] Step 8: (R)-2-(4-methyl-7-(piperidin-3-yl)-7H-imidazo[4,5-c]pyridazin-3-yl)-5-(trifluoromethyl)phenol: A solution of tert-butyl (R)-3-(3-(2-hydroxy-4-(trifluoromethyl)phenyl)-4-methyl-7H-imidazo[4,5-c]pyridazin-7-yl)piperidine-1-carboxylate (503 mg, 1.05 mmol) in DCM (10.5 mL) was treated with HCl (4 M in 1,4-dioxane, 1.32 mL, 5.27 mmol). The reaction mixture was stirred at room temperature for 12 hours. The reaction mixture was then diluted with MeOH and loaded onto a Biotage Isolute® SCX-2 ion exchange column, eluting once with MeOH and once with 7 M ammonia in MeOH. The 7 M ammonia layer was concentrated under reduced pressure to provide the title compound. LCMS [M+H] + = 378.2 (calculated value 378.2).

[0257] Step 9: (R)-2-(4-methyl-7-(1-methylpiperidin-3-yl)-7H-imidazo[4,5-c]pyridazin-3-yl)-5-(trifluoromethyl)phenol: A mixture of (R)-2-(4-methyl-7-(piperidin-3-yl)-7H-imidazo[4,5-c]pyridazin-3-yl)-5-(trifluoromethyl)phenol (20 mg, 0.053 mmol) in MeOH (0.27 mL) and THF (0.27 mL) was treated with formaldehyde (37% in water, 24 μL, 0.318 mmol) and sodium triacetoxyborohydride (34 mg, 0.159 mmol). The reaction mixture was stirred at 25° C. for 1 h. The reaction was then quenched with 4 drops of AcOH and concentrated. The crude residue obtained was taken up in DMSO, filtered, and purified by preparative reverse-phase HPLC (C18 stationary phase, MeCN / water with 0.1% TFA) to provide the title compound.

[0258] LCMS [M+H] + = 392.3 (calculated value 392.2). 1 H NMR (500 MHz, MeOD-d4) δ 8.88 (s, 1H), 7.48 (d, J = 7.8 Hz, 1H), 7.29 (d, J = 8.0 Hz, 1H), 7.24 (s, 1H), 5.10 - 5.00 (m, 1H), 3.40 - 3.28 (m, 2H), 3.08 - 2.88 (m, 2H), 2.51 (s, 3H), 2.51 (s, 3H), 2.36 - 2.21 (m, 2H), 2.04 - 1.83 (m, 2H).

[0259] Table 7. The following compounds were prepared using procedures similar to those described for Example 10 using the appropriate starting materials and aldehydes. [Table 8]

[0260] Table 8. The following intermediates were prepared using procedures similar to that described for Intermediate 3 using the appropriate commercially available amines. [Table 9]

[0261] Table 9. The following intermediates were prepared using procedures similar to those described for Intermediate 6 using the appropriate starting materials. [Table 10]

[0262] Intermediate 18 (4-hydroxybenzo[b]thiophen-5-yl)boronic acid [ka] Step 1: 5,5-dibromo-6,7-dihydrobenzo[b]thiophen-4(5H)-one: A solution of CuBr (5.87 g, 26.3 mmol) in EtOAc (30 mL) was stirred at 80 °C for 10 min. Then, a solution of 6,7-dihydrobenzo-[b]thiophen-4(5H)-one (Combi-Blocks, 1.00 g, 6.57 mmol) in CHCl (30 mL) was added dropwise, and the resulting mixture was stirred at 80 °C for 12 h. The reaction mixture was cooled to room temperature, diluted with EtOAc, and filtered through AlO. The filtrate was washed with saturated aqueous NaHCO, dried over anhydrous NaSO, filtered, and concentrated. The crude residue was purified by silica gel chromatography (EtOAc:petroleum ether) to provide the title compound.

[0263] LCMS [M+H] + = 310.9, (calculated value 310.9).

[0264] Step 2: 5-Bromobenzo[b]thiophen-4-ol: To a solution of 5,5-dibromo-6,7-dihydrobenzo[b]thiophen-4(5H)-one (1.58 g, 5.10 mmol) in DMF (30 mL) was added LiCO (2.26 g, 30.6 mmol). The resulting mixture was stirred at 100 °C for 12 hours. The reaction mixture was then cooled to room temperature, filtered, and concentrated under reduced pressure. The crude residue was purified by silica gel chromatography (EtOAc:petroleum ether) to provide the title compound.

[0265] 1 H NMR (400 MHz, CDCl3) δ 7.51 (d, J = 5.5 Hz, 1H), 7.40 (s, 1H), 7.39 (d, J = 1.7 Hz, 1H), 7.36 - 7.32 (m, 1H), 5.87 (s, 1H).

[0266] Step 3: (4-hydroxybenzo[b]thiophen-5-yl)boronic acid: A mixture of 5-bromobenzo[b]-thiophen-4-ol (400 mg, 1.75 mmol), B2(OH)4 (313 mg, 3.49 mmol), and chloro[(di(1-adamantyl)-n-butylphosphine)-2-(2-aminobiphenyl)]palladium(II) (117 mg, 0.175 mmol) in MeOH (5 mL) was stirred at room temperature under a N2 atmosphere for 12 h. The reaction mixture was then filtered and concentrated under reduced pressure. The crude residue was purified by MPLC (C18 stationary phase, MeCN / water with 0.5% TFA) to give the title compound.

[0267] LCMS [M+H] + = 194.5 (calculated value 195.0).

[0268] Intermediate 19 (4-Hydroxy-2,3-dihydro-1H-inden-5-yl)boronic acid [ka] Step 1: 5-Bromo-2,3-dihydro-1H-inden-4-ol: To a solution of 2,3-dihydro-1H-inden-4-ol (Combi-Blocks, 1.00 g, 7.45 mmol) in DCM (50 mL) was added diisopropylamine (9.1 mg, 0.090 mmol), and the resulting mixture was cooled to 0 °C. To this solution was added 1-bromopyrrolidine-2,5-dione (1.33 g, 7.45 mmol) in small portions. The reaction mixture was allowed to warm to room temperature and stirred for 12 h. The reaction mixture was then washed with water and brine, and the organic layer was dried over anhydrous NaSO, filtered, and concentrated. The crude residue was purified by silica gel chromatography (EtOAc:petroleum ether) to provide the title compound.

[0269] 1 H NMR (400 MHz, CDCl3) δ 7.15 (d, J = 8.0 Hz, 1H), 6.62 (d, J = 8.0 Hz, 1H), 5.43 - 5.32 (m, 1H), 2.83 (dt, J = 17.3, 7.6 Hz, 4H), 2.10 - 1.97 ppm (m, 2H).

[0270] Step 2: (4-Hydroxy-2,3-dihydro-1H-inden-5-yl)boronic acid: A mixture of 5-bromo-2,3-dihydro-1H-inden-4-ol (50 mg, 0.235 mmol), B2(OH)4 (42.1 mg, 0.469 mmol), and chloro[(di(1-adamantyl)-n-butylphosphine)-2-(2-aminobiphenyl)]palladium(II) (15.7 mg, 0.023 mmol) in MeOH (2 mL) was cooled to 0 °C under a N2 atmosphere. DIPEA (0.123 mL, 0.704 mmol) was then added dropwise, and the reaction mixture was then allowed to warm to room temperature and stirred for 12 h. The reaction mixture was then filtered and concentrated under reduced pressure. The resulting crude residue was purified by preparative reverse-phase HPLC (C18 stationary phase, MeCN / water with 0.1% TFA) to provide the title compound.

[0271] LCMS [M+H] + = 179.2 (calculated value 179.1).

[0272] Table 10. The following compounds were prepared using procedures similar to those described for Example 3 using the appropriate starting materials. [Table 11]

[0273] Table 11. The following compounds were prepared using procedures similar to those described for Example 7 using the appropriate starting materials. [Table 12]

[0274] Table 12. The following compounds were prepared using procedures similar to those described for Example 10 using the appropriate starting materials and aldehydes. [Table 13]

[0275] Table 13. The following intermediates were prepared using procedures similar to those described for Intermediate 3 using the appropriate commercially available amines. [Table 14]

[0276] Table 14. The following intermediates were prepared using procedures similar to those described for Intermediate 6 using the appropriate starting materials. [Table 15]

[0277] Intermediate 23 (Alternative Synthesis) tert-Butyl (1R,2R,5R and 1S,2S,5S)-2-(3-chloro-4-methyl-7H-imidazo[4,5-c]pyridazin-7-yl)-8-azabicyclo[3.2.1]octano-8-carboxylate [ka] Step 1: 3,4,6-trichloro-5-methylpyridazine: A solution of 4-bromo-5-methylpyridazine-3,6-diol (Enamine, 1.20 g, 5.85 mmol) and POCl (10 mL, 107 mmol) was stirred at 100 °C for 2 h. The mixture was cooled to room temperature and slowly added to water. The mixture was diluted with EtOAc, the layers were separated, and the aqueous layer was extracted with EtOAc (×2). The combined organic layers were concentrated, and the crude residue was purified by silica gel chromatography (EtOAc:petroleum ether) to provide the title compound.

[0278] LCMS [M+H] + = 197.1 (calculated value 196.9).

[0279] Step 2: Phenyl 3,6-dichloro-5-methylpyridazine-4-sulfinate:A solution of 3,4,6-trichloro-5-methylpyridazine (6.4 g, 32.4 mmol) in THF (50 mL) and DMSO (10 mL) was treated with sodium benzenesulfinate (5.6 g, 34.0 mmol). The resulting reaction mixture was heated to 40° C. for 48 h. The reaction mixture was then cooled to room temperature and diluted with water and EtOAc. The layers were separated, and the aqueous layer was extracted with EtOAc (×3). The combined organic layers were concentrated, and the crude residue was purified by silica gel chromatography (EtOAc:petroleum ether) to provide the title compound.

[0280] LCMS [M+H] + = 303.1 (calculated value 303.0).

[0281] Step 3: tert-butyl (1R,2R,5R and 1S,2S,5S)-2-((6-chloro-5-methyl-4-(phenylsulfonyl)pyridazin-3-yl)amino)-8-azabicyclo[3.2.1]octane-8-carboxylate: A solution of phenyl 3,6-dichloro-5-methylpyridazine-4-sulfinate (580 mg, 1.91 mmol) in 1,4-dioxane (10 mL) was treated with tert-butyl (1R,2R,5R and 1S,2S,5S)-2-amino-8-azabicyclo[3.2.1]octane-8-carboxylate (Combi-Blocks, 433 mg, 1.91 mmol) and Na2CO3 (608 mg, 5.74 mmol). The resulting mixture was heated to 100 °C for 12 h. After cooling to room temperature, the reaction mixture was quenched with water and extracted with EtOAc (3x). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The crude residue was purified by silica gel chromatography (EtOAc:petroleum ether) to provide the title compound.

[0282] LCMS [M+H] + = 493.1 (calculated value 493.2).

[0283] Step 4: tert-Butyl (1R,2R,5R and 1S,2S,5S)-2-((4-azido-6-chloro-5-methylpyridazin-3-yl)amino)-8-azabicyclo[3.2.1]octane-8-carboxylate:A solution of tert-butyl (1R,2R,5R and 1S,2S,5S)-2-((6-chloro-5-methyl-4-(phenylsulfonyl)pyridazin-3-yl)amino)-8-azabicyclo[3.2.1]octane-8-carboxylate (800 mg, 1.62 mmol) in DMF (12 mL) was treated with NaN (844 mg, 13.0 mmol). The resulting mixture was heated to 50 °C for 12 h. After cooling to 0 °C, the reaction mixture was quenched with water and extracted with EtOAc (3 ×). The combined organic layers were washed with brine, dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. The crude residue was purified by silica gel chromatography (EtOAc:petroleum ether) to provide the title compound.

[0284] LCMS [M+H] + = 394.1 (calculated value 394.2).

[0285] Step 5: tert-Butyl (1R,2R,5R and 1S,2S,5S)-2-((4-amino-6-chloro-5-methylpyridazin-3-yl)amino)-8-azabicyclo[3.2.1]octane-8-carboxylate: A solution of tert-butyl (1R,2R,5R and 1S,2S,5S)-2-((4-azido-6-chloro-5-methylpyridazin-3-yl)amino)-8-azabicyclo[3.2.1]octane-8-carboxylate (480 mg, 1.22 mmol) in DCM (5 mL) and AcOH (1 mL) was cooled to 0 °C and treated with zinc (159 mg, 2.44 mmol). The resulting mixture was stirred at 0 °C for 1 h. The reaction mixture was diluted with DCM, then filtered and washed with brine (2 ×). The resulting organic layer was dried over anhydrous Na SO , filtered, and concentrated under reduced pressure to provide the title compound.

[0286] LCMS [M+H] + = 368.1 (calculated value 368.2).

[0287] Step 6: tert-Butyl (1R,2R,5R and 1S,2S,5S)-2-(3-chloro-4-methyl-7H-imidazo[4,5-c]pyridazin-7-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate:A solution of tert-butyl (1R,2R,5R and 1S,2S,5S)-2-((4-amino-6-chloro-5-methylpyridazin-3-yl)amino)-8-azabicyclo[3.2.1]octane-8-carboxylate (240 mg, 0.652 mmol) in trimethyl orthoformate (0.3 mL) was treated with HCl (4 M in 1,4-dioxane, 8.2 μL, 0.033 mmol). The reaction mixture was heated to 100° C. for 30 min. After cooling to room temperature, the reaction mixture was concentrated under reduced pressure. The crude residue was purified by silica gel chromatography (EtOAc:petroleum ether) to provide the title compound.

[0288] LCMS [M+H] + = 378.1 (calculated value 378.2).

[0289] Intermediate 26 5-(3-chloro-4-methyl-7H-imidazo[4,5-c]pyridazin-7-yl)bicyclo[3.1.1]heptan-1-amine [ka] A solution of tert-butyl (5-(3-chloro-4-methyl-7H-imidazo[4,5-c]pyridazin-7-yl)bicyclo[3.1.1]-heptan-1-yl)carbamate (Intermediate 24, 40 mg, 0.106 mmol) in DCM (1 mL) was treated with TFA (36 mg, 0.318 mmol). The resulting mixture was stirred at 20° C. for 1 h. The reaction mixture was then concentrated under reduced pressure, and the crude residue was purified by preparative reverse-phase HPLC (C18 stationary phase, MeCN / water with 0.1% TFA) to provide the title compound.

[0290] LCMS [M+H] + = 278.0, (calculated value 278.1).

[0291] Table 15. The following compounds were prepared using procedures similar to those described for Example 3 using the appropriate starting materials. [Table 16]

[0292] Table 16. The following compounds were prepared using procedures similar to those described for Example 7 using the appropriate starting materials. [Table 17]

[0293] Table 17. The following compounds were prepared using a procedure similar to that described for Example 10, using the appropriate starting material and ketone. DCM was used as the solvent instead of a mixture of THF and MeOH. For Example 22, the reaction temperature was increased to 50°C. [Table 18]

[0294] Examples 24 and 25 2-(7-((1R,2R,5S)-8-azabicyclo[3.2.1]octan-2-yl)-4-methyl-7H-imidazo-[4,5-c]pyridazin-3-yl)-5-(trifluoromethyl)phenol, and 2-(7-((1S,2S,5R)-8-azabicyclo[3.2.1]octan-2-yl)-4-methyl-7H-imidazo-[4,5-c]pyridazin-3-yl)-5-(trifluoromethyl)phenol [ka] Step 1: tert-butyl (1R,2R,5R and 1S,2S,5S)-2-(3-(2-hydroxy-4-(trifluoromethyl)phenyl)-4-methyl-7H-imidazo[4,5-c]pyridazin-7-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate:A solution of tert-butyl (1R,2R,5R and 1S,2S,5S)-2-(3-chloro-4-methyl-7H-imidazo[4,5-c]pyridazin-7-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate (Intermediate 23, 40 mg, 0.106 mmol) and (2-hydroxy-4-(trifluoromethyl)phenyl)boronic acid (Combi-Blocks, 26 mg, 0.127 mmol) in t-AmOH (1 mL) and water (0.2 mL) was treated with cesium carbonate (103 mg, 0.318 mmol) and Ad2n-BuPdG2 (7.1 mg, 0.011 mmol). The reaction mixture was heated to 100 °C for 3 h, then cooled to room temperature and diluted with water and EtOAc. The layers were separated and the aqueous layer was extracted with EtOAc (2x). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated. The crude residue was purified by preparative TLC (EtOAc:petroleum ether) to afford the title compound.

[0295] LCMS [M+H] + = 504.1, (calculated value 504.2).

[0296] Step 2: 2-(7-((1R,2R,5S)-8-azabicyclo[3.2.1]octan-2-yl)-4-methyl-7H-imidazo[4,5-c]pyridazin-3-yl)-5-(trifluoromethyl)phenol and 2-(7-((1S,2S,5R)-8-azabicyclo[3.2.1]octan-2-yl)-4-methyl-7H-imidazo[4,5-c]pyridazin-3-yl)-5-(trifluoromethyl)phenol:A solution of tert-butyl (1R,2R,5R and 1S,2S,5S)-2-(3-(2-hydroxy-4-(trifluoromethyl)phenyl)-4-methyl-7H-imidazo[4,5-c]pyridazin-7-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate (45 mg, 0.089 mmol) in DCM (1 mL) was treated with TFA (51 mg, 0.447 mmol). The resulting mixture was stirred at 20 °C for 1 h. The reaction mixture was then directly concentrated under reduced pressure, and the crude residue was purified by preparative reverse-phase HPLC (C18 stationary phase, MeCN / water with 0.1% TFA). The resulting racemic mixture was separated by chiral method A to give 2-(7-((1R,2R,5S)-8-azabicyclo[3.2.1]octan-2-yl)-4-methyl-7H-imidazo[4,5-c]pyridazin-3-yl)-5-(trifluoromethyl)phenol (Example 24) as the faster eluting isomer and 2-(7-((1S,2S,5R)-8-azabicyclo[3.2.1]octan-2-yl)-4-methyl-7H-imidazo[4,5-c]pyridazin-3-yl)-5-(trifluoromethyl)-phenol (Example 25) as the slower eluting isomer.

[0297] Example 24: LCMS [M+H] + = 404.1, (calculated value 404.2). 1 H NMR (400 MHz, MeOD-d4) δ 8.90 (s, 1H), 7.50 (d, J = 7.9 Hz, 1H), 7.31 (d, J = 7.7 Hz, 1H), 7.26 (s, 1H), 5.13 (br d, J = 10.8 Hz, 1H), 4.22 (br d, J = 5.2 Hz, 1H), 3.79 (br s, 1H), 2.64 (qd, J = 12.7, 5.9 Hz, 1H), 2.54 (s, 3H), 2.27 (br d, J = 12.3 Hz, 1H), 2.09 - 1.78 (m, 6H).

[0298] Example 25: LCMS [M+H] += 404.1, (calculated value 404.2). 1 H NMR (400 MHz, MeOD-d4) δ 8.91 (s, 1H), 7.50 (d, J = 7.7 Hz, 1H), 7.31 (d, J = 8.0 Hz, 1H), 7.26 (s, 1H), 5.16 (br d, J = 11.4 Hz, 1H), 4.30 (br d, J = 5.7 Hz, 1H), 3.88 (br s, 1H), 2.67 (qd, J = 12.7, 6.0 Hz, 1H), 2.54 (s, 3H), 2.29 (br d, J = 13.4 Hz, 1H), 2.14 - 1.83 (m, 6H).

[0299] Example 26 5-chloro-3-fluoro-2-(4-methyl-7-((R)-1-methylpiperidin-3-yl)-7H-imidazo-[4,5-c]pyridazin-3-yl)phenol [ka] Step 1: 3-(4-chloro-2-fluoro-6-methoxyphenyl)-4-methyl-7-((R)-1-methylpiperidin-3-yl)-7H-imidazo[4,5-c]pyridazine: A mixture of (R)-3-chloro-4-methyl-7-(1-methylpiperidin-3-yl)-7H-imidazo[4,5-c]pyridazine (Intermediate 16, 80 mg, 0.300 mmol), (4-chloro-2-fluoro-6-methoxyphenyl)boronic acid (Ambeed, 49 mg, 0.240 mmol), KCO (124 mg, 0.900 mmol), and PdCl(dppf) (22 mg, 0.030 mmol) was treated with 1,4-dioxane (1.25 mL) and water (0.25 mL) under nitrogen. The resulting mixture was heated to 100 °C for 12 h. After cooling to room temperature, the reaction mixture was directly purified by preparative reverse-phase HPLC (C18 stationary phase, MeCN / water with 0.1% TFA) to provide the title compound.

[0300] LCMS [M+H] + = 390.1, (calculated value 390.1). Step 2: 5-chloro-3-fluoro-2-(4-methyl-7-((R)-1-methylpiperidin-3-yl)-7H-imidazo[4,5-c]pyridazin-3-yl)phenol:A solution of 3-(4-chloro-2-fluoro-6-methoxyphenyl)-4-methyl-7-((R)-1-methylpiperidin-3-yl)-7H-imidazo[4,5-c]pyridazine (10 mg, 0.026 mmol) in DCM (1 mL) was cooled to 0 °C and treated with BBr (1 M in heptane, 0.128 mL, 0.128 mmol). The resulting mixture was stirred for 16 h and then allowed to warm slowly to room temperature. The reaction was then cooled to 0 °C, quenched with MeOH, and concentrated. The resulting crude residue was purified by preparative reverse-phase HPLC (C18 stationary phase, MeCN / water + 0.05% FA) to provide the title compound.

[0301] LCMS [M+H] + = 376.2 (calculated value 376.1). 1 H NMR (500 MHz, DMSO-d6) δ 8.86 (s, 1H), 8.46 (d, J = 3.1 Hz, 1H), 6.75 - 6.59 (m, 1H), 4.99 - 4.78 (m, 1H), 2.71 - 2.62 (m, 2H), 2.35 (s, 3H), 2.26 (s, 3H), 2.21 - 2.11 (m, 2H), 1.83 - 1.62 (m, 2H), 1.27 - 1.20 (m, 1H), 0.83 (dt, J = 21.3, 6.6 Hz, 1H).

[0302] Example 27 (R)-3-Cyclopropyl-2-fluoro-6-(4-methyl-7-(1-methylpiperidin-3-yl)-7H-imidazo-[4,5-c]pyridazin-3-yl)phenol [ka] Step 1: (R)-3-(4-chloro-3-fluoro-2-methoxyphenyl)-4-methyl-7-(1-methylpiperidin-3-yl)-7H-imidazo[4,5-c]pyridazine:A mixture of (R)-3-chloro-4-methyl-7-(1-methylpiperidin-3-yl)-7H-imidazo[4,5-c]pyridazine (Intermediate 16, 100 mg, 0.376 mmol), 2-(4-chloro-3-fluoro-2-methoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (AOB Chem, 108 mg, 0.376 mmol), KCO (156 mg, 1.13 mmol), and PdCl(dppf) (28 mg, 0.038 mmol) was treated with 1,4-dioxane (3.1 mL) and water (0.63 mL) under nitrogen. The resulting mixture was heated to 100 °C for 12 h. The reaction mixture was then cooled to room temperature and directly concentrated under reduced pressure. The resulting crude residue was dissolved in DMSO, filtered, and purified by preparative reverse-phase HPLC (C18 stationary phase, MeCN / water with 0.1% TFA). The desired fractions were collected and then diluted with EtOAc, water, and saturated aqueous NaHCO. The layers were separated, and the aqueous layer was extracted with EtOAc (2x). The combined organic layers were dried over anhydrous MgSO, filtered, and concentrated under reduced pressure to provide the title compound.

[0303] LCMS [M+H] + = 390.2, (calculated value 390.1).

[0304] Step 2: (R)-3-(4-cyclopropyl-3-fluoro-2-methoxyphenyl)-4-methyl-7-(1-methylpiperidin-3-yl)-7H-imidazo[4,5-c]pyridazine: A mixture of (R)-3-(4-chloro-3-fluoro-2-methoxyphenyl)-4-methyl-7-(1-methylpiperidin-3-yl)-7H-imidazo[4,5-c]pyridazine (33 mg, 0.085 mmol) and PdCl(dppf) (6.2 mg, 0.0085 mmol) in 1,4-dioxane (0.85 mL) was treated with cyclopropylzinc(II) bromide (0.5 M in THF, 0.51 mL, 0.254 mmol) under nitrogen. The resulting mixture was heated to 70 °C for 3 h. After cooling to room temperature, the reaction mixture was quenched with saturated aqueous NH Cl and extracted with EtOAc (4x). The combined organic layers were dried over anhydrous MgSO, filtered, and concentrated under reduced pressure. The resulting crude residue was then purified by preparative reverse phase HPLC (C18 stationary phase, MeCN / water with 0.1% TFA) to afford the title compound.

[0305] LCMS [M+H] + = 396.3 (calculated value 396.2).

[0306] Step 3: (R)-3-cyclopropyl-2-fluoro-6-(4-methyl-7-(1-methylpiperidin-3-yl)-7H-imidazo[4,5-c]pyridazin-3-yl)phenol: A solution of (R)-3-(4-cyclopropyl-3-fluoro-2-methoxyphenyl)-4-methyl-7-(1-methylpiperidin-3-yl)-7H-imidazo[4,5-c]pyridazine (15 mg, 0.038 mmol) in DCM (1.5 mL) was cooled to 0 °C and treated with BBr (1 M in heptane, 0.190 mL, 0.190 mmol). The resulting mixture was stirred for 16 h and then allowed to warm slowly to room temperature. After cooling to 0 °C, the reaction was quenched by the dropwise addition of MeOH and concentrated under reduced pressure. The resulting crude residue was purified by preparative reverse-phase HPLC (C18 stationary phase, MeCN / water + 0.05% FA) to provide the title compound.

[0307] LCMS [M+H] + = 382.3 (calculated value 382.2). 1 H NMR (500 MHz, DMSO-d6) δ 8.88 (s, 1H), 8.47 (d, J = 5.5 Hz, 1H), 6.97 (d, J = 8.1 Hz, 1H), 6.53 (s, 1H), 4.88 (d, J = 9.6 Hz, 1H), 3.06 - 3.00 (m, 1H), 2.72 - 2.62 (m, 2H), 2.39 (s, 3H), 2.27 (s, 3H), 2.23 - 2.06 (m, 3H), 1.83 - 1.64 (m, 2H), 1.02 (d, J = 8.4 Hz, 2H), 0.89 - 0.79 (m, 1H), 0.78 (d, J = 5.2 Hz, 2H).

[0308] Examples 28 and 29 2-(4-methyl-7-((1S,2S,5R)-8-methyl-8-azabicyclo[3.2.1]octan-2-yl)-7H-imidazo-[4,5-c]pyridazin-3-yl)-5-(trifluoromethyl)phenol, and 2-(4-methyl-7-((1R,2R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-2-yl)-7H-imidazo-[4,5-c]pyridazin-3-yl)-5-(trifluoromethyl)phenol [ka] Step 1: tert-butyl (1R,2R,5R and 1S,2S,5S)-2-(3-(2-hydroxy-4-(trifluoromethyl)phenyl)-4-methyl-7H-imidazo[4,5-c]pyridazin-7-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate: A solution of tert-butyl (1R,2R,5R and 1S,2S,5S)-2-(3-chloro-4-methyl-7H-imidazo[4,5-c]pyridazin-7-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate (Intermediate 23, 40 mg, 0.106 mmol) and (2-hydroxy-4-(trifluoromethyl)phenyl)boronic acid (Combi-Blocks, 26 mg, 0.127 mmol) in t-AmOH (1 mL) and water (0.2 mL) was treated with cesium carbonate (103 mg, 0.318 mmol) and Ad2n-BuPdG2 (7.1 mg, 0.011 mmol). The reaction mixture was heated to 100 °C for 3 h, then cooled to room temperature and diluted with water and EtOAc. The layers were separated, and the aqueous layer was extracted with EtOAc (2x). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The crude residue was then purified by preparative TLC (EtOAc:petroleum ether) to afford the title compound.

[0309] LCMS [M+H] + = 504.1, (calculated value 504.2).

[0310] Step 2: 2-(7-((1R,2R,5S and 1S,2S,5R)-8-azabicyclo[3.2.1]octan-2-yl)-4-methyl-7H-imidazo[4,5-c]pyridazin-3-yl)-5-(trifluoromethyl)phenol: A solution of tert-butyl (1R,2R,5R and 1S,2S,5S)-2-(3-(2-hydroxy-4-(trifluoromethyl)phenyl)-4-methyl-7H-imidazo[4,5-c]pyridazin-7-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate (35 mg, 0.070 mmol) in DCM (0.7 mL) was treated with TFA (40 mg, 0.348 mmol). The reaction mixture was stirred at 20 °C for 1 h. The reaction mixture was then washed with saturated aqueous NaHCO and concentrated under reduced pressure to provide the title compound, which was used in the next step without further purification.

[0311] LCMS [M+H] + = 404.2, (calculated value 404.2).

[0312] Step 3: 2-(4-methyl-7-((1R,2R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-2-yl)-7H-imidazo[4,5-c]pyridazin-3-yl)-5-(trifluoromethyl)phenol and 2-(4-methyl-7-((1S,2S,5R)-8-methyl-8-azabicyclo[3.2.1]octan-2-yl)-7H-imidazo[4,5-c]pyridazin-3-yl)-5-(trifluoromethyl)phenol:A solution of 2-(7-((1R,2R,5S and 1S,2S,5R)-8-azabicyclo[3.2.1]octan-2-yl)-4-methyl-7H-imidazo[4,5-c]pyridazin-3-yl)-5-(trifluoromethyl)phenol (28 mg, 0.069 mmol) and formaldehyde (17 mg, 0.21 mmol) in MeOH (1 mL) was cooled to 0 °C, and sodium cyanoborohydride (22 mg, 0.347 mmol) was added. The resulting reaction mixture was warmed to 25 °C and stirred for 30 min. The reaction mixture was then directly concentrated under reduced pressure, and the crude residue was purified by preparative reverse-phase HPLC (C18 stationary phase, MeCN / water with 0.1% TFA). The resulting racemic mixture was separated by chiral method B to give 2-(4-methyl-7-((1S,2S,5R)-8-methyl-8-azabicyclo[3.2.1]octan-2-yl)-7H-imidazo[4,5-c]pyridazin-3-yl)-5-(trifluoromethyl)phenol (Example 28) as the faster eluting isomer and 2-(4-methyl-7-((1R,2R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-2-yl)-7H-imidazo[4,5-c]pyridazin-3-yl)-5-(trifluoromethyl)phenol (Example 29) as the slower eluting isomer.

[0313] Example 28: LCMS [M+H] + = 418.1, (calculated value 418.2). 1 H NMR (400 MHz, MeOD-d4) δ 8.90 (s, 1H), 7.49 (d, J = 8.0 Hz, 1H), 7.30 (d, J = 8.2 Hz, 1H), 7.24 (s, 1H), 5.20 - 5.10 (m, 1H), 3.98 (br d, J = 2.9 Hz, 1H), 3.48 (br s, 1H), 2.57 - 2.49 (m, 7H), 2.33 - 2.16 (m, 2H), 2.11 - 1.96 (m, 2H), 1.95 - 1.80 (m, 3H). Example 29: LCMS [M+H] + = 418.1, (calculated value 418.2).1 H NMR (400 MHz, MeOD-d4) δ 8.89 (s, 1H), 7.49 (d, J = 8.0 Hz, 1H), 7.30 (d, J = 7.9 Hz, 1H), 7.24 (s, 1H), 5.19 - 5.05 (m, 1H), 3.92 (br d, J = 4.4 Hz, 1H), 3.40 (br s, 1H), 2.51 (d, J = 16.6 Hz, 7H), 2.27 - 2.13 (m, 2H), 2.09 - 1.96 (m, 2H), 1.92 - 1.80 (m, 3H).

[0314] Table 18. The following compounds were prepared using the appropriate starting materials following procedures similar to those described for Examples 28 and 29. Racemic products were separated using the chiral SFC method specified in the table; for pairs of enantiomers, the faster-eluting isomer is listed first.

[0315] [Table 19]

[0316] Example 32 2-(7-(5-aminobicyclo[3.1.1]heptan-1-yl)-4-methyl-7H-imidazo[4,5-c]pyridazin-3-yl)-5-(trifluoromethyl)phenol [ka] A solution of 5-(3-chloro-4-methyl-7H-imidazo[4,5-c]pyridazin-7-yl)bicyclo[3.1.1]heptan-1-amine (Intermediate 26, 12 mg, 0.042 mmol) and (2-hydroxy-4-(trifluoromethyl)phenyl)boronic acid (Combi-Blocks, 9.8 mg, 0.043 mmol) in t-AmOH (0.5 mL) and water (0.1 mL) was treated with cesium carbonate (42 mg, 0.130 mmol) and Ad2n-BuPdG2 (2.9 mg, 0.0043 mmol). The reaction mixture was heated to 100 °C under nitrogen for 2 h, then cooled to room temperature and extracted with EtOAc (2x). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The resulting crude residue was purified by preparative reverse phase HPLC (C18 stationary phase, MeCN / water + 0.05% NH4OH + 10 mM NH4HCO3) to afford the title compound.

[0317] LCMS [M+H] + = 404.1, (calculated value 404.2). 1 H NMR (400 MHz, MeOD-d4) δ 8.64 (s, 1H), 7.49 (d, J = 7.7 Hz, 1H), 7.30 (d, J = 7.4 Hz, 1H), 7.24 (s, 1H), 2.76 - 2.66 (m, 2H), 2.57 - 2.46 (m, 5H), 2.40 - 2.32 (m, 2H), 2.15 - 2.04 (m, 2H), 1.99 - 1.86 (m, 2H).

[0318] Table 19. The following compounds were prepared using the appropriate intermediates following a procedure similar to that described for Example 32. Racemic products were separated using the chiral SFC method specified in the table; for pairs of enantiomers, the faster-eluting isomer is listed first. [Table 20]

[0319] Example 35 (R)-2-(4-methyl-7-(1-methyl-d 3 )piperidin-3-yl)-7H-imidazo[4,5-c]pyridazin-3-yl)-5-(trifluoromethyl)phenol [ka] A solution of (R)-2-(4-methyl-7-(piperidin-3-yl)-7H-imidazo[4,5-c]pyridazin-3-yl)-5-(trifluoromethyl)phenol (Example 5, 40 mg, 0.106 mmol) in MeOD-d (0.21 mL) was cooled to 0 °C and treated with deuterated formaldehyde (20 wt% in DO, 85 μL, 0.530 mmol) and NaBD (13.3 mg, 0.318 mmol). The resulting mixture was slowly warmed to 25 °C and stirred for 12 h. The reaction mixture was then directly concentrated under reduced pressure, and the crude residue was purified by preparative reverse-phase HPLC (C stationary phase, MeCN / water with 0.1% TFA). Fractions containing the title compound were combined and treated with saturated aqueous NaHCO to neutralize the pH, then extracted with EtOAc (3x). The combined organic layers were dried over anhydrous MgSO4, filtered, and concentrated to give the title compound.

[0320] LCMS [M+H] + = 395.3 (calculated value 395.2). 1 H NMR (500 MHz, DMSO-d6) δ 8.88 (s, 1H), 7.48 (d, J = 7.8 Hz, 1H), 7.30 (d, J = 8.1 Hz, 1H), 7.26 (s, 1H), 4.87 (t, J = 9.6 Hz, 1H), 3.59 - 3.51 (m, 2H), 2.69 (br s, 1H), 2.38 (s, 3H), 2.26 - 2.03 (m, 3H), 1.76 (br s, 1H), 1.69 (d, J = 10.2 Hz, 1H).

[0321] Pharmaceutical Composition Examples In a specific embodiment of the oral pharmaceutical composition, a 100 mg tablet is composed of 100 mg of any one of the above examples, 268 mg of microcrystalline cellulose, 20 mg of croscarmellose sodium, and 4 mg of magnesium stearate. The active substance, microcrystalline cellulose, and croscarmellose are first mixed. The mixture is then lubricated with magnesium stearate and compressed into tablets.

[0322] Biological assays Activation of the canonical NLRP3 inflammasome requires two steps: priming and activation. Priming signals, such as pathogen-activating molecular patterns (PAMPs) or danger-activating molecular patterns (DAMPs), are recognized by Toll-like receptors (TLRs), triggering nuclear factor-κB (NF-κB)-mediated signaling, which results in the transcriptional upregulation of inactive NLRP3 and inflammasome-associated components, including prolL-1β (Bauernfeind et al., J. Immunol. 2009, 183, 787–791; Franchi et al., Nat. Immunol. 2012, 13, 325–332; Franchi et al., J. Immunol. 2014, 193, 4214–4222). The second step is activation, which induces NLRP3 oligomerization, followed by the assembly of NLRP3, apoptosis-associated speck-like protein containing CARD (ASC), and procaspase-1 to form the inflammasome complex, which triggers the conversion of procaspase-1 to caspase-1 and the production and secretion of mature IL-1β and IL-18 (Kim et al., J. Inflamm. 2015, 12, 41; Ozaki et al., J. Inflamm. Res. 2015, 8, 15-27; Rabeony et al., Eur. J. Immunol. 2015, 45, 2847). Upon assembly of the inflammasome complex, NLRP3 oligomerization triggers ASC nucleation and an event commonly referred to as "ASC SPECK" formation, which appears as discrete punctate structures within the cell after ASC staining and visualization using standard immunocytochemical methods.

[0323] The ability of compounds to inhibit NLRP3 inflammasome activation was measured in vivo by monitoring the formation of ASC-SPECK in human monocytic THP-1 cells after stimulation. THP-1 cells (ATCC catalog #TIB-202) were maintained in complete growth medium containing Roswell Park Memorial Institute RPMI (ATCC catalog #30-2001), 10% heat-inactivated fetal bovine serum, 1X penicillin / streptomycin, and 0.05 mM 2-mercaptoethanol. At the start of the assay, undifferentiated THP-1 cells were plated at a density of 20,000 cells per well in 384-well plates (poly-D-lysine-coated Cell Carrier Ultra microplates, Perkin Elmer catalog #6057500) in complete growth medium supplemented with 10 ng / mL phorbol 12-myristate 13-acetate (PMA; Sigma catalog #P8139) and then incubated overnight. The next day, the medium was replaced with assay medium [RPMI (Gibco catalog #11875-093), 0.01% bovine serum albumin (BSA)]. Compounds were serially diluted in DMSO and then added to the wells 1 hour before the addition of 12.5 μg / mL gramicidin (Enzo Lifescience, catalog #ALX-350-233-M005). All incubations were performed at 37°C (5% CO2 / 95% air). After 3 hours of gramicidin treatment, cells were fixed with 4% paraformaldehyde and stored at 4°C until immunofluorescence staining.

[0324] Immunofluorescence staining:Anti-ASC antibody (MBL catalog #D086-3) was desalted and labeled with the Alexa 488 antibody labeling kit (Thermo catalog #A20181) before use as described below. After fixation, the following steps were performed at room temperature. Cells were first permeabilized with 0.3% Triton X-100 in phosphate-buffered saline (PBS) for 15 minutes and then incubated for 1 hour in blocking buffer containing 5% goat serum, 0.3% Tween-20, and 0.03% sodium azide in PBS. Cells were stained for 1 hour with a mixture of ASC-Alexa 488 antibody (diluted 1:200 in blocking buffer) and the nuclear stain DRAQ5 (1:5000 in blocking buffer, Thermo catalog #62251). After washing with 0.3% Tween-20 in PBS, plates were imaged using the Opera Phoenix High Content Screening System. The number of DRAQ5-positive cells, including ASC SPECKS, was quantified in each well.

[0325] Data Analysis: EC 50 Values ​​were calculated by standard curve fitting analysis using an in-house developed program, TIBCO Spotfire software.

[0326] The compounds of the present invention inhibit activation of the NLRP3 inflammasome in the above biological assays and have an EC 50 The specific EC values ​​of the compounds of Examples 1 to 35 in the above biological assays are 50 The values ​​are listed in Table I.

[0327] [Table 21] TIFF0007815552000058.tif62165

[0328] The scope of the claims should not be limited by the preferred embodiments set forth in the examples, but should be accorded the broadest interpretation consistent with the specification as a whole.

[0329] While the present disclosure has been described and illustrated with reference to certain specific embodiments thereof, those skilled in the art will understand that various adaptations, changes, modifications, substitutions, deletions, or additions to the procedures and protocols may be made without departing from the scope of the present disclosure. For example, effective dosages other than the specific dosages set forth hereinabove may be applied as a result of variations in the responsiveness of mammals treated for any indication with a compound of structural formula I shown above. The specific pharmacological response observed may vary according to or depending on the presence or absence of the particular active compound or pharmaceutical carrier selected, as well as the type of formulation and mode of administration employed. Such expected variations or differences in results are contemplated in accordance with the objectives and practice of the present disclosure.

Claims

1. Structural formula I: 【Chemistry 1】 [During the ceremony, X is ═N—; R １ teeth, (1) bicyclo[3.1.1]heptane, (2) piperidine, (3) 8-azabicyclo[3.2.1]octane, and (4) octahydroindolizine, wherein R １ is unsubstituted or R ａ substituted with 1 to 6 substituents selected from: R ２ is -CH ３ and R ３ is phenyl, wherein the phenyl is unsubstituted or R ｃ substituted with 1 to 5 substituents selected from: R ５ is hydrogen or -C １－６ alkyl, where each alkyl is unsubstituted or R ｅ substituted with 1 to 5 substituents selected from: Each R ａ teeth, (1) CN, (2) oxo, (3) —OH, (4) halogens, (5)-C １－６ Alkyl, (6)-C １－６ alkyl-OH, (7) -O-C １－６ Alkyl, (8)-C ３－６ cycloalkyl, (9)-C １－６ Alkyl-C ３－６ cycloalkyl, (10)-(CH ２ ) ｐ -S(O) ｒ R ｆ , and (11)-N(R ｇ ) ２ wherein each CH ２ , alkyl and cycloalkyl are independently unsubstituted or substituted with halogen, CF ３ , O.H., C. １－６ Alkyl and —OC １-６ substituted with 1 to 6 substituents selected from alkyl; Each R ｃ teeth, (1) -OH, (2) Cl, (3) F, (4)-CH ３ 、 (5)-CF ３ 、 (6)-OCHF ２ 、 (7) cyclopropyl, and (8)-NH ２ 、 are independently selected from the group Each R ｅ teeth, (1) hydrogen, (2) OH, (3) halogens, and (4)-C １－６ Alkyl are independently selected from the group Each R ｆ teeth, (1) hydrogen, (2)-C １－６ Alkyl, (3)-C ３－６ cycloalkyl, and (4)-C ２－６ cycloheteroalkyl are independently selected from the group Each R ｇ teeth, (1) hydrogen, (2)-C １－６ Alkyl, (3)-C ３－６ cycloalkyl, (4)-C ２－６ cycloheteroalkyl, (5) aryl, (6) heteroaryl, (7) -C(O)C １－６ Alkyl, and (8)-S(O) ｒ R ｆ wherein alkyl is unsubstituted or is selected from the group consisting of CF ３ , halogen, OH and —OC １－６ may be substituted with 1 to 3 substituents selected from alkyl; p is 0, 1, 2, 3, 4, 5 or 6; and r is 1 or 2. or a pharmaceutically acceptable salt thereof.

2. R ５ is hydrogen; 2. The compound of claim 1 or a pharmaceutically acceptable salt thereof.

3. R １ is a bicyclo[3.1.1]heptane, which is unsubstituted or ａ substituted with 1 to 6 substituents selected from:

2. The compound of claim 1 or a pharmaceutically acceptable salt thereof.

4. R １ is 8-azabicyclo[3.2.1]octane, where R １ is unsubstituted or R ａ substituted with 1 to 6 substituents selected from:

2. The compound of claim 1 or a pharmaceutically acceptable salt thereof.

5. below, (1) (R)-2-(4-methyl-7-(piperidin-3-yl)-7H-imidazo[4,5-c]pyridazin-3-yl)-5-(trifluoromethyl)phenol; (2) (3S,4R)-3-(3-(2-hydroxy-4-(trifluoromethyl)phenyl)-4-methyl-7H-imidazo[4,5-c]pyridazin-7-yl)piperidin-4-ol; (3) (R)-2-(7-(1-ethylpiperidin-3-yl)-4-methyl-7H-imidazo[4,5-c]pyridazin-3-yl)-5-(trifluoromethyl)phenol; (4) (R)-3-(2-(difluoromethoxy)-4-(trifluoromethyl)phenyl)-7-(1-ethylpiperidin-3-yl)-4-methyl-7H-imidazo[4,5-c]pyridazine; (5) (3S,4R)-3-(3-(2-hydroxy-4-(trifluoromethyl)phenyl)-4-methyl-7H-imidazo[4,5-c]pyridazin-7-yl)-1-methylpiperidin-4-ol; and, (6) (3S,4R)-1-ethyl-3-(3-(2-hydroxy-4-(trifluoromethyl)phenyl)-4-methyl-7H-imidazo[4,5-c]pyridazin-7-yl)piperidin-4-ol; (7) (R)-5-chloro-2-(4-methyl-7-(piperidin-3-yl)-7H-imidazo[4,5-c]pyridazin-3-yl)phenol; (8) (R)-2-(4,6-dimethyl-7-(1-methylpiperidin-3-yl)-7H-imidazo[4,5-c]pyridazin-3-yl)-5-(trifluoromethyl)phenol; and, (9) (R)-5-chloro-2-(7-(1-ethylpiperidin-3-yl)-4-methyl-7H-imidazo[4,5-c]pyridazin-3-yl)phenol; or a pharmaceutically acceptable salt thereof.

6. 10. A pharmaceutical composition comprising the compound of claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

7. 10. Use of a compound of claim 1, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament useful for the treatment of a disorder, condition, or disease responsive to the inhibition of NLRP3 in a mammal in need thereof.

8. 10. Use of a compound of claim 1 or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment, prevention or control of an inflammatory, fibrotic, cardiovascular, metabolic or neurodegenerative disorder.

9. 9. The use according to claim 8, wherein the disorder is an inflammatory disorder.

10. 10. The use according to claim 9, wherein the inflammatory disorder is selected from an autoimmune disorder, an autoinflammatory disorder, an inflammatory joint disorder, an inflammatory skin disorder and a neuroinflammatory disorder.

11. 8. The use according to claim 7, wherein the disorder is selected from atherosclerosis, non-alcoholic steatohepatitis, Alzheimer's disease and Parkinson's disease.

12. 10. A compound according to claim 1 or a pharmaceutically acceptable salt thereof for use in therapy.

13. 10. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 or 5, or a pharmaceutically acceptable salt thereof, for treating or preventing a disorder, condition, or disease responsive to the inhibition of NLRP3.

14. 14. The pharmaceutical composition of claim 13, wherein the disorder is selected from an inflammatory disorder, a fibrotic disorder, a cardiovascular disorder, a metabolic disorder, and a neurodegenerative disorder.

15. 15. The pharmaceutical composition of claim 14, wherein the disorder is an inflammatory disorder.

16. 16. The pharmaceutical composition of claim 15, wherein the inflammatory disorder is selected from an autoimmune disorder, an autoinflammatory disorder, an inflammatory joint disorder, an inflammatory skin disorder, and a neuroinflammatory disorder.

17. 14. The pharmaceutical composition of claim 13, wherein the disorder is selected from atherosclerosis, non-alcoholic steatohepatitis, Alzheimer's disease, and Parkinson's disease.

18. A compound selected from the following, or a pharmaceutically acceptable salt thereof: (1) (R)-2-(7-(1-ethylpiperidin-3-yl)-7H-pyrrolo[2,3-c]pyridazin-3-yl)-3-methyl-5-(trifluoromethyl)phenol; (2) (R)-2-(7-(1-ethylpiperidin-3-yl)-4-methyl-7H-pyrrolo[2,3-c]pyridazin-3-yl)-5-(trifluoromethyl)phenol; (3) (R)-2-(7-(1-ethylpiperidin-3-yl)-7H-imidazo[4,5-c]pyridazin-3-yl)-3-methyl-5-(trifluoromethyl)phenol; (4) (R)-2-(7-(1-methylpiperidin-3-yl)-7H-imidazo[4,5-c]pyridazin-3-yl)-5-(trifluoromethyl)phenol; (5) (S)-2-(7-(1-methylpiperidin-3-yl)-7H-imidazo[4,5-c]pyridazin-3-yl)-5-(trifluoromethyl)phenol; (6) (R)-5-(4-methyl-7-(1-methylpiperidin-3-yl)-7H-imidazo[4,5-c]pyridazin-3-yl)benzo[b]thiophen-4-ol; (7) (R)-5-(4-methyl-7-(1-methylpiperidin-3-yl)-7H-imidazo[4,5-c]pyridazin-3-yl)-2,3-dihydro-1H-inden-4-ol; (8) (R)-5-(4-methyl-7-(piperidin-3-yl)-7H-imidazo[4,5-c]pyridazin-3-yl)-2,3-dihydro-1H-inden-4-ol, and (9) (R)-2,2-Difluoro-5-(4-methyl-7-(1-methylpiperidin-3-yl)-7H-imidazo[4,5-c]pyridazin-3-yl)-2,3-dihydro-1H-inden-4-ol.

19. A compound selected from the following, or a pharmaceutically acceptable salt thereof: (1) (R)-3-methyl-2-(7-(1-methylpiperidin-3-yl)-7H-imidazo[4,5-c]pyridazin-3-yl)-5-(trifluoromethyl)phenol; (2) (S)-3-methyl-2-(7-(1-methylpiperidin-3-yl)-7H-imidazo[4,5-c]pyridazin-3-yl)-5-(trifluoromethyl)phenol; (3) (R)-2-(4-methyl-7-(1-methylpiperidin-3-yl)-7H-imidazo[4,5-c]pyridazin-3-yl)-5-(trifluoromethyl)phenol; (4) (R)-5-chloro-2-(4-methyl-7-(1-methylpiperidin-3-yl)-7H-imidazo[4,5-c]pyridazin-3-yl)phenol; (5) 5-chloro-3-fluoro-2-(4-methyl-7-((R)-1-methylpiperidin-3-yl)-7H-imidazo[4,5-c]pyridazin-3-yl)phenol; and (6) (R)-2-(4-methyl-7-(1-(methyl-d ３ )piperidin-3-yl)-7H-imidazo[4,5-c]pyridazin-3-yl)-5-(trifluoromethyl)phenol.

20. A compound selected from the following, or a pharmaceutically acceptable salt thereof: (1) (R)-2-fluoro-3-methyl-6-(4-methyl-7-(1-methylpiperidin-3-yl)-7H-imidazo[4,5-c]pyridazin-3-yl)phenol; (2) (R)-2-(7-(1-isopropylpiperidin-3-yl)-4-methyl-7H-imidazo[4,5-c]pyridazin-3-yl)-5-(trifluoromethyl)phenol; (3) (R)-2-(7-(1-cyclobutylpiperidin-3-yl)-4-methyl-7H-imidazo[4,5-c]pyridazin-3-yl)-5-(trifluoromethyl)phenol; (4) 2-(7-((1R,2R,5S)-8-azabicyclo[3.2.1]octan-2-yl)-4-methyl-7H-imidazo[4,5-c]pyridazin-3-yl)-5-(trifluoromethyl)phenol; (5) 2-(7-((1S,2S,5R)-8-azabicyclo[3.2.1]octan-2-yl)-4-methyl-7H-imidazo[4,5-c]pyridazin-3-yl)-5-(trifluoromethyl)phenol; (6) (R)-3-cyclopropyl-2-fluoro-6-(4-methyl-7-(1-methylpiperidin-3-yl)-7H-imidazo[4,5-c]pyridazin-3-yl)phenol; (7) 2-(4-methyl-7-((1S,2S,5R)-8-methyl-8-azabicyclo[3.2.1]octan-2-yl)-7H-imidazo[4,5-c]pyridazin-3-yl)-5-(trifluoromethyl)phenol; (8) 2-(4-methyl-7-((1R,2R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-2-yl)-7H-imidazo[4,5-c]pyridazin-3-yl)-5-(trifluoromethyl)phenol; (9) 2-(7-((1R,2R,5S)-8-ethyl-8-azabicyclo[3.2.1]octan-2-yl)-4-methyl-7H-imidazo[4,5-c]pyridazin-3-yl)-5-(trifluoromethyl)phenol; (10) 2-(7-((1S,2S,5R)-8-ethyl-8-azabicyclo[3.2.1]octan-2-yl)-4-methyl-7H-imidazo[4,5-c]pyridazin-3-yl)-5-(trifluoromethyl)phenol; (11) 2-(7-(5-aminobicyclo[3.1.1]heptan-1-yl)-4-methyl-7H-imidazo[4,5-c]pyridazin-3-yl)-5-(trifluoromethyl)phenol; (12) 2-(4-methyl-7-((8S,8aR)-octahydroindolizin-8-yl)-7H-imidazo[4,5-c]pyridazin-3-yl)-5-(trifluoromethyl)phenol; and (13) 2-(4-methyl-7-((8R,8aS)-octahydroindolizin-8-yl)-7H-imidazo[4,5-c]pyridazin-3-yl)-5-(trifluoromethyl)phenol.

21. A compound which is (R)-2-(4-methyl-7-(piperidin-3-yl)-7H-imidazo[4,5-c]pyridazin-3-yl)-5-(trifluoromethyl)phenol or a pharmaceutically acceptable salt thereof.

22. A compound which is (R)-2-(4-methyl-7-(1-methylpiperidin-3-yl)-7H-imidazo[4,5-c]pyridazin-3-yl)-5-(trifluoromethyl)phenol or a pharmaceutically acceptable salt thereof.

23. A compound which is 2-(7-((1R,2R,5S)-8-azabicyclo[3.2.1]octan-2-yl)-4-methyl-7H-imidazo[4,5-c]pyridazin-3-yl)-5-(trifluoromethyl)phenol or a pharmaceutically acceptable salt thereof.

24. A compound which is 2-(7-((1S,2S,5R)-8-azabicyclo[3.2.1]octan-2-yl)-4-methyl-7H-imidazo[4,5-c]pyridazin-3-yl)-5-(trifluoromethyl)phenol or a pharmaceutically acceptable salt thereof.

25. A compound which is 2-(4-methyl-7-((1S,2S,5R)-8-methyl-8-azabicyclo[3.2.1]octan-2-yl)-7H-imidazo[4,5-c]pyridazin-3-yl)-5-(trifluoromethyl)phenol or a pharmaceutically acceptable salt thereof.

26. A compound which is 2-(4-methyl-7-((1R,2R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-2-yl)-7H-imidazo[4,5-c]pyridazin-3-yl)-5-(trifluoromethyl)phenol or a pharmaceutically acceptable salt thereof.

27. A compound which is 2-(7-(5-aminobicyclo[3.1.1]heptan-1-yl)-4-methyl-7H-imidazo[4,5-c]pyridazin-3-yl)-5-(trifluoromethyl)phenol or a pharmaceutically acceptable salt thereof.

Images